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Abstract
The metastatic pattern of advanced CRC is somehow homogeneous. Liver
is the most frequently affected organ, followed by the lung, peritoneum and
bone. We studied the mechanisms driving the metastatic spread in CRC,
focusing in the MAPK pathway. We developed in vivo a highly metastatic
cell line using a KRAS-mutated cell line (SW620) in an ortothopic xenograft
mouse model and used both in vivo and in vitro experiments to evaluate the
mechanisms of metastasis. We also used data from two large prospective
cohorts of incident CRC to evaluate the association of an intronic variant
of SMAD7 (rs4939827, 18q21) with the phenotype and molecular charac-
terisitics of CRC. This variant is associated with a lower risk of developing
CRC (odds ratio of 0.88, 95% confidence interval [CI] 0.85 - 0.93) and a
poorer survival after diagnosis (hazards ratio of 1.16, 95% CI 1.06-1.27).
In the first project, where we evaluated the mechanisms of metastasis, we
introduced in the SW620 cell line an expression vector for luciferase, which
allowed us to monitor the kinetics of emergence of liver metastatic lesions
by quantitative bioluminescence imaging. The SW620 luciferase-expressing
cells were inoculated into portal circulation of immunodeficient mice via
intrasplenic injection followed by splenectomy, in order to isolate cell pop-
ulations that target the liver. Second, the SW620-derived liver metastases
were expanded in culture and the resulting population (Liver Metastatic
derivative, LiM1) was subjected to a second round of in vivo selection, pro-
ducing the LiM2 cell population that showed a significant increase in liver
and lung metastatic activity. Comparative transcriptomic analysis identi-
fied 194 genes differentially expressed between the parental and the highly
metastatic cell line. This colon cancer metastatic gene set was contrasted
against a cohort of 267 patients with stage I-III CRC and we investigated
the signaling pathways regulating the expression of a set of genes with in-
creased metastatic capacity. We found pathways of nitrogen metabolism,
cell adhesion molecules and mitogen-activated protein kinases (MAPKs).
We focused on the MAPKs given the KRAS -mutated status of our cell line
(and because patients harboring certain mutations in KRAS/BRAF have
fewer therapeutic options that patients without them), finding that the ac-
tivating phosphorylation of ERK1/ERK2 was increased, the p38 MAPKs
was reduced and the phosphorylation of JNKs did not change. Downregula-
tion of ERK2 (but not of ERK1) in the highly metastatic cell line reverted
its metastatic capacity to the liver, but not to the lung in our mice model.
We thus hypothesized that the ability to metastasize the lung by the highly
metastatic derivative had to be driven by other mechanism.
The analysis of clinical samples evidenced that tumor biopsies with low
phospho-38 MAPK were associated with metastasis to the lung but not to
other organs. Treating mice harboring liver metastasis from the parental
cell line with a p38 MAPK specific inhibitor produced an increase in the
percentage of mice with lung metastasis. We validated this finding with a
different cell line and different experimental setting. Conversely, activation
of the p38 MAPK pathway by expression of MKK6EE (MKK6 is a MAP
kinase-kinase that phosphorylates and activates p38 MAP kinase) dimin-
ished the lung metastatic capacity of the HCT116 cell line.
The expression of parathyroid hormone-like hormone (PTHLH ) was up-
regulated (3.3 fold) in our highly metastatic derivative and was inversely
correlated with the expression of MKK6 in CRC primary tumors. Downreg-
ulation of PHTLH in the highly metastatic derivative decreased its capacity
to colonize the lung without decreasing its capacity to colonize the liver af-
ter intra portal inoculation. Interestingly, tail vein (draining directly to
the lungs) injections of the highly metastatic derivative did not yield any
lung metastasis and silencing PHTLH in LiM2 cells did not affect its growth
when injected directly into the lung. This suggested that the role of PTHLH
in regulating lung metastasis did not depended on growth promotion but
more probably on extravasation. This was supported by an experiment
where we injected in the tail vein LiM2 cells overexpressing or not PTHLH:
mice injected with LiM2 cells overexpressing PTHLH presented a five-fold
increase in the number of cells extravasated in the lungs. We finally ev-
idenced that PTHLH induced apoptosis of human pulmonary endothelial
cells (HPEC) by increasing Ca+ levels that in turn induces mobilization of
the apoptosis-inducing factor mitochondrion-associated 1 (AIFM1), from
the mitochondria to the cytosol, a caspase-independent cell death mecha-
nism. This disrupts the lung vasculature increasing the permeability of the
lung to metastatic cells.
In the second project, where we evaluate the association of the SMAD7
intronic variant with tumor phenotype and several CRC molecular char-
acteristics, we used 1509 CRC cases and 2307 age-matched controls nested
within the Nurses Health Study (NHS) and the Health Professionals Follow-
up Study (HPFS). NHS and HPFS are cohorts of healthy individuals that
record information biennially, with a follow-up greater than 90%. Samples
for DNA extraction (blood or buccal cell specimens) from both cohorts were
obtained in more than 90,000 individuals. Information on CRC is extracted
from medical records from participants who reported CRC in the bien-
nial questionnaires. We randomly selected between one and three controls
(matched on ethnicity, year of birth and month/year of sampling) within
the same cohort from participants who were free of CRC at the same time
the CRC was diagnosed in the cases.
Among the 1509 cases with blood or buccal samples in this study, we were
able to successfully obtain tissue suitable for molecular analyses in 658 cases.
We genotyped rs4939827 (TaqMan R©) successfully in 98% of the samples in
NHS and 99.6% of the samples in HPFS. The phenotipic features evalu-
ated were: TNM stage, grade of differentiation, location of the primary
tumor (colon vs. rectum) and age at diagnosis. The evaluated molecular
characteristics were DNA methylation of RUNX3 and LINE-1 (long inter-
spersed nucleotide element-1), CpG island methylator phenotype (CIMP),
microsatellite instability, TP53 expression by immunohistochemistry and
the mutational status of BRAF, KRAS and PIK3CA.
We modeled each SNP using a log-additive approach, relating genotype dose
(i.e. number of copies of the minor allele) to risk of CRC. We adjusted all
analyses for age at sample collection, race, gender, aspirin use, non-steroidal
anti-inflammatory drugs use, body mass index, physical activity, familial
history of CRC, smoking, alcohol, meat consumption, energy-adjusted cal-
cium and folate intake and type of sample (blood versus cheek). To assess
heterogeneity in the association between rs4939827 and tumors according to
clinical phenotype or molecular characteristics, we used a case-case design
using logistic regression model comparing tumor subtypes.
We found that the minor allele (G) in rs4939827 was associated with a lower
risk of developing tumor stage pT1 or pT2 CRC [multivariate odds ratio
(OR), 0.73; 95% confidence interval (CI) 0.62-0.87] but not tumor stage pT3
or pT4 (multivariate OR, 1.07; 95% CI 0.93-1.23, P for heterogeneity = 1.2
x 10−4). The association between rs4939827 and CRC also significantly
differed by methylation of RUNX3 (P for heterogeneity = 0.005). Among
those with CRC, the minor allele (G) in rs4939827 was significantly associ-
ated with poorer overall survival (hazards ratio, 1.20; 95% CI, 1.02-1.42).
We performed mediation analyses to decompose the total effect of the ex-
posure (rs4939827) on the outcome (T3-T4 tumors) into a “direct effect”
plus an “indirect effect” The “direct effect” can be interpreted as the OR
comparing the risk of T3-T4 tumor stage with the genetic variant present
vs. absent if the mediator (e.g. RUNX3) were what it would have been
without the genetic variant. The “indirect effect” can be interpreted as the
OR for T3-T4 tumor stage for those with the genetic variant present com-
paring the risk if the mediator were what it would have been with versus
without the genetic variant.
The multivariate ORs that estimate the direct effect of rs4939827 were 1.96
(95% CI 1.18-3.25, P-value = 0.009) for one variant allele and 4.46 (95% CI
1.19-16.6, P-value = 0.038) for two variant alleles. The multivariate ORs
estimating the indirect effect of rs4939827 on risk of pT3 and pT4 tumors
was 1.05 (95% CI 0.96-1.15, P = 0.32) for one variant allele and 1.50 (95%
CI 0.44-5.10, P = 0.51) for two variant alleles. We did not found evidence
of neither multiplicative nor additive interaction between rs4939827 and
RUNX3 methylation.
In conclusion, we provide clinical and molecular evidence showing that
ERK2 activation provides colon cancer cells with the ability to seed and col-
onize the liver and reduced p38 MAPK signalling endows cancer cells with
the ability to form lung metastasis from previously established liver lesions.
Downregulation of p38 MAPK signalling results in increased expression of
the cytokine PTHLH, which contributes to colon cancer cell extravasation
to the lung by inducing caspase-independent death in endothelial cells of
the lung microvasculature. We also show that patients with the rs4939827
CRC-susceptibility locus diagnosed with CRC tend to develop tumors with
greater invasiveness (as measured by the pT stage). The variant rs4939827
is differentially associated with RUNX3 methylation status, supporting an
effect of rs4939827 or causal variants tagged by this SNP on carcinogenesis
mediated through the TGFβ pathway. Taken together, these results could
explain, at least in part, the lower risk of CRC associated with the G allele
of rs4939827 yet poorer survival.
Resumen
El patro´n de meta´stasis de ca´ncer de colon y recto (CCR) avanzado es rel-
ativamente homoge´neo. El h´ıgado es el o´rgano ma´s frecuentemente afec-
tado, seguido del pulmo´n, el peritoneo y huesos. Parte de esta inves-
tigacio´n consiste en explorar los mecanismos involucrados en el patro´n
metasta´tico de CCR, focaliza´ndonos en la v´ıa biolo´gica de MAPK. Para
ello usamos una l´ınea celular (SW620) con el gen KRAS mutado como
punto de partida para crear un derivado con alta capacidad metasta´tica
mediante un modelo animal basado en la inyeccio´n de ce´lulas tumorales
en la circulacio´n portal de ratones inmunodeprimidos. Adema´s realizamos
experimentos tanto in vivo como in vitro para desarrollar los hallazgos.
Asimismo usamos datos procedentes de dos cohortes en las que se identifi-
caron CCR incidentes, en los que se evaluo´ la asociacio´n entre el polimor-
fismo intro´nico de SMAD7 (rs4939827, 18q21) con el genotipo y carac-
ter´ısticas tumorales. Este polimorfismo esta´ asociado con un menor riesgo
de desarrollar CCR (odds ratio 0.88, 95% confidence interval [CI] 0.85 -
0.93) y con peor prono´stico entre aquellos pacientes diagnosticados con CCR
(hazards ratio of 1.16, 95% CI 1.06-1.27).
En el primer proyecto, donde evaluamos los mecanismos de meta´stasis, in-
trodujimos en la l´ınea celular SW620 un vector de expresio´n de luciferasa, lo
cual permite monitorizar y cuantificar la emergencia de lesiones metasta´ticas
in vivo mediante bioluminiscencia. Estas ce´lulas marcadas son inoculadas
en la circulacio´n portal de los ratones inmunodeficientes mediante su in-
yeccio´n en el bazo, tras lo cual los esplenectomizamos. Cuando el rato´n
reproduce meta´stasis hepa´ticas, se recuperan e´stas y se a´ıslan las ce´lulas
metasta´ticas (que las denominamos LiM1), sometie´ndolas a otro ciclo ide´ntico
de enriquecimiento de su capacidad metasta´tica mediante una nueva in-
yeccio´n intraesple´nica. Las ce´lulas enriquecidas a partir de las meta´stasis
resultantes (LiM2) muestran una alta capacidad metasta´tica a h´ıgado y a
pulmo´n.
Mediante ana´lisis de expresio´n de genes usando chips de transcripcio´n iden-
tificamos 194 genes diferencialmente expresados entre las l´ıneas parentales
(SW620) y las ce´lulas altamente metasta´ticas (LiM2). Esta “firma” gene´tica
se contrasto´ con una cohorte cl´ınica de 267 pacientes con CCR estadios I-
III y asimismo investigamos las v´ıas biolo´gicas que podr´ıan estar regulando
el conjunto de genes que identificamos como asociados a mayor capaci-
dad metasta´tica. Encontramos que las siguientes v´ıas biolo´gicas estaban
involucradas: metabolismo del nitro´geno, mole´culas de adhesio´n celular y
mitogen-activated protein kinases (MAPKs). Decidimos centrarnos en la v´ıa
de MAPKs ya que las ce´lulas con las que trabajamos ten´ıan el gen KRAS
mutado y adema´s porque los pacientes que sufren un cancer de colon avan-
zado con KRAS mutado tienen menos opciones terape´uticas. Encontramos
que la fosforilacio´n de ERK1/ERK2 estaba aumentada, que las MAPKs
p38 estaban disminuidas y que la fosforilacio´n de JNKs no hab´ıa cambiado.
Evidenciamos adema´s que, en nuestro modelo animal, el silenciamiento de
ERK2 (pero no de ERK1) en la l´ınea celular altamente metasta´tica revierte
su capacidad metasta´tica al h´ıgado, pero no al pulmo´n. Esto nos llevo´ a
hipotetizar que la capacidad de metastatizar en el pulmo´n de la l´ınea celular
altamente metasta´tica deb´ıa de estar mediado por algu´n otro mecanismo.
El ana´lisis de muestras cl´ınicas mostro´ que aquellos pacientes cuyo tumor
presentaba bajos niveles de p38 sufr´ıan una mayor frecuencia de meta´stasis
al pulmo´n, pero no a otros o´rganos. Al tratar ratones que hab´ıan desarrol-
lado meta´stasis hepa´ticas derivadas de la l´ınea celular parental con un in-
hibidor espec´ıfico de p38, vimos que se incrementaba la afinidad metasta´tica
al pulmo´n. Este hallazgo lo validamos con una l´ınea celular diferente
(HCT116) en un modelo animal tambie´n diferente. Tambie´n evidenciamos
que si activa´bamos la v´ıa de p38 mediante la induccio´n de MKK6EE (MKK6
es una MAP kinase-kinase que fosforila y activa la kinasa p38), la capacidad
de metastatizar al pulmo´n de la l´ınea celular HCT116 disminu´ıa.
La expresio´n de PTHLH (parathyroid hormone-like hormone) presentaba
un aumento relativo de 3,3 veces en la l´ınea celular altamente metasta´tica
comparada con la l´ınea parental. Asimismo, PTHLH se correlacionaba in-
versamente con la expresio´n de MKK6 en tumores primarios de colon. Evi-
denciamos que el silenciamiento de PTHLH en el derivado celular altamente
metasta´tico disminu´ıa su capacidad de colonizar el pulmo´n, sin afectar su
capacidad de colonizar el h´ıgado tras su inyeccio´n en el sistema portal.
La inyeccio´n el la vena de la cola del rato´n (que drena directamente al
pulmo´n) del derivado celular altamente metasta´tico no produc´ıa meta´stasis
pulmonares y el silenciamiento de PTHLH en estas ce´lulas no afectaba su
crecimiento si se inyectaban directamente en el pulmo´n. Esto nos llevo´ a
pensar que el papel de PTHLH en la regulacio´n de las meta´stasis hepa´ticas
no era a trave´s de un incremento de la proliferacio´n, sino a trave´s de un in-
cremento en la capacidad de extravasarse. Para confirmar esto inyectamos
ce´lulas LiM2 que sobreexpresaban o no PTHLH en la cola de los ratones
(drenando directamente al pulmo´n): encontramos que aquellos ratones a los
que se les inyectaron ce´lulas LiM2 que sobreexpresaban PTHLH presenta-
ban cinco veces ma´s ce´lulas extravasadas que los ratones a los que se les in-
yectaron ce´lulas LiM2 sin sobreexpresio´n de PTHLH. Finalmente pudimos
demostrar que PTHLH induce la apoptosis de ce´lulas humanas de endotelio
pulmonar incrementando los niveles de calcio intracelulares, lo que causa
la movilizacio´n del factor AIFM1(apoptosis-inducing factor mitochondrion-
associated 1 ) de la mitocondria al citoplasma, induciendo la apoptosis celu-
lar mediante un mecanismo independiente de caspasas. Esto desestructura
la vasculatura pulmonar, facilitando que las ce´lulas metasta´ticas puedan
extravasarse al pulmo´n.
En el segundo proyecto evaluamos la asociacio´n de un polimorfismo intro´nico
del gen SMAD7 con el fenotipo y varias caracter´ısticas moleculares del tu-
mor. Para ello empleamos 1509 casos de ca´ncer de colon y recto y 2307 con-
troles emparejados anidados en las cohortes Nurses Health Study (NHS) y
Health Professionals Follow-up Study (HPFS). NHS y HPFS son cohortes de
individuos sanos cuando fueron reclutados y que han facilitado informacio´n
sobre su salud y sus ha´bitos de vida cada dos aos, siendo el seguimiento
superior al 90%. Las muestras para la extraccio´n del DNA (sangre o frotis
de mejilla) se obtuvieron en ma´s de 90.000 individuos. En los casos, la in-
formacio´n sobre el diagno´stico del tumor se extrajo de las historias me´dicas.
Seleccionamos 1-3 controles emparejados en raza, ao de nacimiento y fecha
de muestreo por cada control, dentro de la cohorte de pacientes sin CCR
cuando el caso fue diagnosticado.
De entre los 1509 casos con muestra de DNA, pudimos obtener tejido
tumoral apropiado para realizar su ana´lisis molecular en 658 casos. El
genotipo del polimorfismo rs4939827 (TaqMan R©) se realizo´ correctamente
en el 98% de las muestras de la cohorte NHS y en el 99.6% de las muestras
de la cohorte HPFS. Los rasgos fenot´ıpicos que evaluamos fueron: el esta-
dio TNM, grado de diferenciacio´n, localizacio´n del tumor primario (colon
vs. recto) y edad al diagno´stico. Las caracter´ısticas moleculares que anal-
izamos fueron la metilacio´n de RUNX3 y LINE-1 (long interspersed nu-
cleotide element-1), la metilacio´n de las islas de CpG (CIMP), inestabilidad
de microsate´lites, la expresio´n por inmunohistoqu´ımica de TP53 y el estado
mutaciones de BRAF, KRAS y PIK3CA.
Para el ana´lisis estad´ıstico modelamos el polimorfismo usando un modelo
log-aditivo que relacionaba la “dosis” de genotipo (el nu´mero de copias del
alelo de menor frecuencia con el riesgo de CCR. Ajustamos los ana´lisis
por la edad en el momento de recogida de la muestra, raza, sexo, uso de
aspirina, uso de antiinflamatorios no esteroideos, ı´ndice de masa corporal,
actividad f´ısica, historia familiar de CCR, tabaquismo, alcohol, consumo
de carne, consumo de calcio y folato y tipo de muestra para la obtencio´n
de DNA (sangre o frotis de mejilla). Para evaluar la heterogeneidad en la
asociacio´n entre el polimorfismo de rs4939827 y los tumores de acuerdo al
fenotipo cl´ınico o caracter´ısticas moleculares, usamos un diseo “caso-caso”
comparando los diferentes subgrupos tumorales usando regresio´n log´ıstica.
Encontramos que el alelo de menor frecuencia de rs4939827 (G) se asociaba
con un menor riesgo de desarrollar un CCR con un estadio pT1 o pT2
[razo´n de odds (OR) ajustada, 0.73; intervalo de confianza al 95% (CI)
0.62-0.87] pero no con tumores con estadio pT3 o pT4 (OR ajustada, 1.07;
95% CI 0.93-1.23, valor p de heterogeneidad = 1.2 x 10−4). La asociacio´n
entre el polimorfismo de rs4939827 y CCR tambie´n difer´ıa significativamente
segu´n la metilacio´n de RUNX3 (valor p de heterogeneidad = 0.005). Entre
aquellos pacientes diagnosticados con CCR, el alelo de menor frecuencia
de rs4939827 (G) estaba significativamente asociado con pero supervivencia
(hazards ratio, 1.20; 95% CI, 1.02-1.42).
Realizamos adema´s un ana´lisis de mediacio´n para descomponer el efecto
total de la exposicio´n de intere´s (rs4939827) en la variable dependiente (tu-
mores pT3-pT4) en un efecto directo ma´s un efecto indirecto. El efecto
directo se puede interpretar como la razo´n de odds que compara el riesgo
de presentar un tumor pT3-pT4 estando el polimorfismo de rs4939827 pre-
sente vs. ausente si el valor del mediador (RUNX3) fuera aquel que corre-
sponde a la ausencia del polimorfismo de rs4939827. El efecto indirecto se
puede interpretar como la razo´n de odds de presentar un tumor pT3-pT4
para aquellos pacientes con la presencia del polimorfismo de rs4939827 com-
parada con el riesgo si el mediador fuera el que corresponde a tener o no
dicho polimorfismo.
La razo´n de odds ajustada que estima el efecto directo de rs4939827 fue 1.96
(95% CI 1.18-3.25, valor p = 0.009) para la presencia de un alelo y de 4.46
(95% CI 1.19-16.6, valor p = 0.038) para la presencia de dos alelos. La razo´n
de odds ajustada que estima el efecto indirecto de rs4939827 en el riesgo de
tumores pT3-pT4 fue 1.05 (95% CI 0.96-1.15, P = 0.32) para la presencia
de un alelo y 1.50 (95% CI 0.44-5.10, P = 0.51) para la presencia de dos
alelos. No encontramos evidencia de interaccio´n en la escala multiplicativa
o aditiva entre rs4939827 y la metilacio´n de RUNX3.
Como conclusio´n, en el presente trabajo hemos hallado evidencia que mues-
tra que la activacio´n de ERK2 hace que las ce´lulas de ca´ncer de colon tengan
la habilidad de colonizar el h´ıgado y que una disminucio´n de los niveles de
p38 hace que las ce´lulas tumorales puedan generar meta´stasis pulmonares
a partir de meta´stasis hepa´ticas previamente establecidas. Esta dismin-
ucio´n de p38 hace que aumente la expresio´n de la citoquina PTHLH, lo
cual contribuye a facilitar la extravasacio´n al pulmo´n mediante la induccio´n
de muerte celular de las ce´lulas endoteliales de la microvasculatura pul-
monar. Tambie´n hemos encontrado evidencia de que los pacientes con el
polimorfismo rs4939827 (el cual se asocia a mayor incidencia de CCR) tienen
mayor riesgo de desarrollar tumores ma´s invasivos (con mayor estadio pT).
Este polimorfismo esta´ asimismo asociado diferencialmente con el estado de
metilacio´n de RUNX3, lo cual apoyar´ıa que el efecto de rs4939827 (o de
polimorfismos causales surrogados por e´ste) puede estar mediado por la v´ıa
molecular de TGFβ. Estos hallazgos pueden ayudar a explicar por que´ el
alelo de menor frecuencia de rs4939827 se asocia con menor riesgo de desar-
rollar CCR en individuos sanos, y con peor supervivencia en los pacientes
diagnosticados de CCR.
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GLOSSARY
AIFM1: Apoptosis-inducing factor
mitochondrion-associated 1.
APC: Adenomatous polyposis coli.
CI: Confidence interval.
CCM: Colon cancer metastatic gene
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1Introduction
1.1 Epidemiology of colorectal cancer
1.1.1 Incidence and mortality
Worldwide, colorectal cancer (CRC) is the second most common cancer in women and
the third most common in men, with 614,000 and 746,000 cases in 2012 respectively. Ge-
ographical variation in incidence across the world is notorious: Australia/New Zealand
harbor the highest estimated incidences (44.8 and 32.2 cases per 100,000 in men and
women respectively) and Western Africa has the lowest estimated incidences (4.5 and
3.8 per 100,000). Figure 1.1 represents the global incidence age-standardized rates for
men and women respectively. CRC accounts approximately for 8.5% (694,000 deaths
in 2012) of the cancer mortality worldwide (1).
In Spain, the incidence of CRC is similar as it is worldwide, with 19,261 cases in
men (44 cases per 100,000) and 12,979 cases in women (24.2 cases per 100,000) in 2012
(1). CRC is the second cause of cancer mortality in men (first is lung cancer: 27.4% of
cancer deaths) with 8,742 deaths (13.7 % of cancer deaths) in 2012. In women, CRC
is also the second cause of cancer mortality (first is breast cancer: 15.5% of cancer
deaths) with 5,958 deaths (15.2 % of cancer deaths) in 2012 (1). Figure 1.2 represents
incidence and mortality age-standardized rates by sex of the 10 most frequent cancers.
1.1.2 Genetic susceptibility
Inherited susceptibility accounts for about 30% of all cases of CRC (2). The majority
of the CRC are sporadic (as opposed to familial).
1
1. INTRODUCTION
No Data
<4.9
4.9-8.3
8.3-14.3
14.3-26.3
26.3+
Colorectal cancers
Source: GLOBOCAN 2012 (IARC)
Incidence ASR
Both sexes
Figure 1.1: Global age-standardized colorectal cancer incidence rates - Source:
GLOBOCAN
Figure 1.2: Incidence and mortality age-standardized rates by sex for the 10
most frequent cancers in Spain - Source: GLOBOCAN
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1.1.2.1 Genetic susceptibility due to common variants
Genome-wide association studies (GWAS) have allowed the study of common single
nucleotide polymorfisms (SNP –A SNP is a DNA variant that represents a variation in
a single base– (3)) and CRC.
The main role of GWAS in CRC has been shedding light into the biology of the
disease rather than providing practical risk stratification of the overall population (as
opposed to familial syndromes, where their diagnosis conditions the screening and clin-
ical management of the patients, often with preventive interventions). GWAS have
identified over 30 CRC susceptibility SNPs corresponding to more than 20 loci (sum-
marized in Table 1.1). Still, the majority of the phenotypic variance seems to be
unaccounted for, coining the term missing heritability (4).
The challenges of studying the effect of common variants in CRC are that (i) the
magnitude of the effect of the SNP in the disease risk is small and (ii) GWAS studies
survey hundreds of thousands of base pairs. As a consequence the required sample
size inflates (a small effect of the exposure increases the type II error and multiple
comparisons increase the type I error) and these studies are thus feasible mainly inside
large consortia that have the capacity to genotype thousands of individuals.
One of the earliest identified and most consistently validated variants is rs4939827
(18q21.1), which seems to be specific for CRC. Table 1.2 summarizes the studies sup-
porting this association.
The SNP rs4939827 maps within intron 3 of the gene SMAD family member 7
(SMAD7 ), which is associated with the TGFβ (transforming growth factor-β) pathway.
Specifically, SMAD7 acts as an intracellular antagonist of TGFβ signaling by binding
stably to the receptor complex and blocking activation of downstream signaling (24).
The minor allele (G) in rs4939827 is associated with a lower risk of CRC, with the
most recent GWAS observing an odds ratio (OR) of 0.88 [95% confidence interval (CI)
0.85-0.93, P-value = 1.1× 10−7] (23). Recently, in a pooled analysis of five prospective
cohorts, we observed that the G allele is also associated with poorer survival [hazard
ratio (HR) = 1.16, P-value = 0.02] (25).
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SNP Locus Closest gene References
rs6691170 1q41 DUSP10 Houlston et al. 2010 (5)
rs6687758 1q41 DUSP10 Houlston et al. 2010 (5)
rs11903757 2q32.3 NABP1 Peters et al. 2013 (6)
rs10936599 3q26.2 MYNN Houlston et al. 2010 (5)
rs35509282 4q32.2 FSTL5 Stenzel et al. 2014 (7)
rs647161 5q31.1 AK026965 Jia et al. 2013 (8)
rs1321311 6p21 CDKN1A Dunlop et al. 2012 (9)
rs7758229 6q25.3 SLC22A3 Cui et al. 2011 (10)
rs16892766 8q23.3 EIF3H Tomlinson et al. 2008 (11)
rs10505477 8q24 MYC Zanke et al. 2007 (12), Gruber et al. 2007 (13)
rs6983267 8q24 MYC Zanke et al. 2007 (12), Haiman et al. 2007 (14),
Tomlinson et al. 2007 (15), Hutter et al. 2010 (16)
rs7014346 8q24 MYC Tenesa et al. 2008 (17)
rs719725 9p24 TPD52L3 Tomlinson et al. 2008 (11), Kocarnik et al. 2010
(18)
rs10795668 10p14 LOC338591 Tomlinson et al. 2008 (11)
rs3824999 11q13.4 POLD3 Dunlop et al. 2012 (9)
rs3802842 11q23 C11orf93 Tenesa et al. 2008 (17)
rs10774214 12p13.32 CCND2 Jia et al. 2013 (8)
rs7136702 12q13.12 LARP4 Houlston et al. 2010 (5)
rs11169552 12q13.12 LARP4 Houlston et al. 2010 (5)
rs4444235 14q22.2 BMP4 Houlston et al. 2008 (19), Tomlinson et al. 2011
(20)
rs1957636 14q22.2 BMP4 Tomlinson et al. 2011 (20)
rs16969681 15q13.3 CRAC1,HMPS,
GREM1
Tomlinson et al. 2011 (20)
rs4779584 15q13.3 CRAC1,HMPS,
GREM1
Jaeger et al. 2008 (21), Tomlinson et al. 2011 (20)
rs11632715 15q13.3 CRAC1,HMPS,
GREM1
Tomlinson et al. 2011 (20)
rs9929218 16q22.1 CDH1 Houlston et al. 2008 (19)
rs4939827 18q21 SMAD7 Broderick et al. 2007 (22), Tenesa et al. 2008 (17)
rs10411210 19q13.1 RHPN2 Houlston et al. 2008 (19)
rs961253 20p12.3 BMP2 Houlston et al. 2008 (19), Tomlinson et al. 2011
(20)
rs4813802 20p12.3 BMP2 Tomlinson et al. 2011 (20), Peters et al. 2012 (23)
rs4925386 20q13.33 LAMA5 Houlston et al. 2010 (5)
rs5934683 Xp22.2 SHROOM2 Dunlop et al. 2012 (9)
Table 1.1: SNPs associated with CRC risk4
1.1 Epidemiology of colorectal cancer
Reference Population RAF OR (95% CI)
Broderick et al.(22) Discovery: 930 Eu ancestry cases, 960 Eu
ancestry controls
0.52 1.16 (1.09-1.27)
Replicaton: 7473 Eu ancestry cases, 5984
Eu ancestry controls
Tenesa et al.(17) Discovery: 981 Eu ancestry cases, 1002 Eu
ancestry controls
0.52 1.20 (1.16-1.24)
Replication: 10287 Eu ancestry cases,
10401 Eu ancestry controls, 4400 Jap an-
cestry cases, 3179 Jap ancestry controls,
1789 other ancestry cases, 1771 other an-
cestry controls
Tomlinson et al.(11) Discovery: 930 Eu ancestry cases, 960 Eu
ancestry controls
0.53 1.18 (1.10-1.25)
Replication: 17089 Eu ancestry cases,
16862 Eu ancestry controls, 783 Other an-
cestry cases, 664 Other ancestry controls
Peters et al. (23) Discovery: 2906 Eu descent cases, 3416 Eu
descent controls
0.51 1.14 (1.08-1.18)
Replication: 8161 Eu descent cases, 9101
Eu descent controls
Peters et al. (6) Discovery: 2696 Eu ancestry colorectal tu-
mor cases, and 15113 Eu ancestry controls
0.52 1.12 (1.09-1.16)
Replication: 958 Eu ancestry colorectal
tumor cases, 2098 EA ancestry colorec-
tal tumor cases, 909 Eu ancestry controls,
5749 EA ancestry controls
Table 1.2: GWAS studies identifying rs4939827 as a risk SNP for CRC. RAF:
Risk Allele Frequency; OR: Odds Ratio; CI: Confidence Interval; Eu: European; Jap:
Japanese; EA: East Asian
5
1. INTRODUCTION
1.1.2.2 Hereditary syndromes
High-penetrance germ line mutations in known genes account for around 5-7% of the
cases (26). The most relevant are:
1. Lynch syndrome or hereditary non-polyposis colorectal cancer (HN-
PCC). HNPCC is an autosomal dominant syndrome that accounts for approxi-
mately 3 to 5 percent of CRC. Families diagnosed with Lynch syndrome usually
have a germline mutation in one allele of a mismatch repair (MMR) gene, usually
hMLH1, hMSH2, hMSH6, or PMS2. Mutations in EpCAM can induce a MSH2
mono allelic methylation. Phenotypically these are early (mean age at diagnosis
is 48 years) right-sided CRC. Lynch syndrome also increases the risk of cancer in
other locations (endometrium, ovary, stomach, small bowel) (27, 28).
2. Familial adenomatous polyposis (FAP). FAP accounts for less than 1 percent
of CRC. It is caused by germline mutations in the adenomatous polyposis coli
(APC ) gene. Sites of mutation in the APC gene can have different degree of
phenotypic impact. Patients present with multiple polyps in the colon and develop
CRC by age 45 in 90% of the cases (29).
3. MUTYH -associated polyposis. Patients with this disease mimic the FAP
phenotype due to biallelic germline mutations in the base excision repair (the
base excision repair system repairs mutations due to oxidative DNA damage)
gene mutY homolog (MUTYH ) (30).
1.2 Biology of colorectal cancer tumor progression
The transformation of the healthy colorectal mucosa into adenoma and CRC is a well
documented process that involves the sequential alteration of several pathways: Wnt
pathway through the loss of APC or through the accumulation of nuclear β-catenin,
the acquisition of constitutive active mutations of KRAS or BRAF, mutations in the
PI3K pathway, loss of the 18q chromosome and inactivation of SMAD4 and TP53 (31).
Specifically:
1. Adenomatous Polyposis Coli (APC ) gene and Wnt signaling pathway.
APC is a tumor suppressor gene. Somatic mutations in both alleles are present in
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a high percent of sporadic CRCs. As mentioned above, a single germline mutation
in this gene is responsible for the FAP syndrome. APC loss is considered a very
early event in CRC development (32). The Wnt pathway is an evolutionarily
conserved signal transduction pathway that plays a central role in supporting
intestinal epithelial renewal (33). The main tumor supressor funcion of APC
is to destabilize free β-catenin. Therefore, the loss of APC causes nuclear β-
catenin accumulation. Free β-catenin (either because of loss of APC or because
mutations in β-catenin that stabilized it and cannot be degraded) leads to Wnt
pathway activation (e.g. through activation of Tcf4) and an increase in size of
the proliferating crypt compartment in the colon mucosa.
2. Transfroming growth factor β (TGFβ). TGFβ signaling pathway plays a
role in the control of cell proliferation, migration, differentiation and apoptosis
and is commonly disregulated in CRC. Key elements of this pathway are the three
TGFβ isoforms (TGFβ1-3, being the TGFβ1 the most commonly expressed iso-
form), the TGFβ receptors (TGFβR1 and TGFβR2) and the downstream tran-
scription factors SMAD2, SMAD3 and SMAD4. The activation of the pathway
ends up with a SMAD complexes (SMAD2, SMAD3 and SMAD4) translocat-
ing to the nucleus to regulate several TGFβ-responsive genes. Some of these
TGFβ-responsive genes are important cell cycle checkpoint genes. In normal ep-
ithelium, TGFβ acts as a tumor suppressor. However, once cells are resistant to
TGFβ-mediated proliferative inhibition (i.e. in established tumors), TGFβ ap-
pears to promote metastasis by enhancing angiogenesis and extracellular matrix
disruption and inhibiting infiltrating tumor immune cells (34). SMAD7 acts as
a downstream inhibitor of the action of TGFβ. TGFβ-related ligands can ac-
tivate other pathways beyond SMADs, like MAPK pathway, JNK pathway and
phosphatidylinositol 3-kinases/Akt (PI3K-Act) pathway (35).
3. RAS. Ras proteins are GTPases encoded by different variants of the RAS onco-
gene. These variants are H-ras, K-ras and N-ras. Ras proteins regulate different
signaling pathways involved in the control of cell behavior like proliferation, dif-
ferentiation, migration, survival and apoptosis (36). Best known effectors of Ras
GTPases are Raf kinases and phosphatidylinositol 3-kinases. RAS mutations are
found in up to 50 % of sporadic CRC. K-ras has been reported to be implicated
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in the processes of colorectal cancer invasion and metastasis (37). Mutations of
RAS are clinically relevant because their presence impedes response to mono-
clonal antibodies against the epidermal growth factor receptor (EGFR) (38) like
cetuximab and panitumumab.
1.3 Mechanisms of metastasis
Each tumor type has a characteristic metastatic pattern and latency (e.g. prostate
cancer has a tendency to metastasize to the bone whereas breast cancer spreads mainly
to the bone, lung, brain and liver). In the case of CRC, distant metastasis appear
primarily in the liver and second, by far, in the lung and bones. In some tumours
like breast cancer important advances have been achieved in unveiling the metastatic
process (39). Nevertheless, these cannot be directly extrapolated to CCR given its
different metastatic behaviour.
The vascular drainage of the colon may play a role in this characteristic pattern of
spread (40) as the mesenteric circulation drains to the liver, therefore those CRC cells
detached from the primary tumor reach the liver capillary network as a first station
for colonization. But beyond this passive role of circulation pattern, metastatic cells
must gain additional functions to form macroscopic metastases. The development of
metastasis reflect the evolutionary process involved in cancer, where the mediators of
metastasis act as factors that slightly increase, cell by cell, the probability of successful
completion of one or more steps of the metastatic process. The main steps are the
following.
1.3.1 Angiogenesis
When circulating tumor cells arrive to a distant organ, one of the main stressors that
they face is the lack of oxygen and nutrients. Thus their survival depends on a shift on
the normal balance of angiogenesis. One of the main factors involved in angiogenesis
is the vascular endothelial growth factor (VEGF). Some genes associated with higher
metastatic capacity do so by increasing the angiogenic potential of the invading cells.
As an example, EREG, COX-2 and MMP-1 cooperate in remodeling the vasculature
by allowing neoangiogenesis in models of breast cancer (41). As another example, the
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lack of oxygen stabilizes the hypoxia-inducible factor (HIF) which in turn activates me-
diators of angiogenesis (42). Several antiangiogenic drugs have been approved recently
for the treatment of metastatic CRC.
1.3.2 Stroma activation
Tumor cells need to interact with the stroma to enter the circulation and have the
possibility of reaching distant organs (43). They also need to interact with the stroma
of the distant organ in orden to colonize it. Various stromal cell types can induce
signals that cancer cells will use for survival, invasiveness, self-renewal, and migration.
As an example, cancer cells interact with astrocytes in the brain parenquima to form
brain metastasis (44, 45) and with osteoclasts in the bone marrow to form osteoclastic
metastasis (46). This process is well characterized in breast cancer, where the PI3K-
Akt pathway is involved in facilitating bone metastasis (via activation of CXCL12
and IGF1) (47) and the Noch and Wnt pathways are involved in lung metastasis (via
periostin and protein tenascin c interaction) (48). The stroma of the tumor itself can
also promote the attachment of circulating tumor cells favoring its clonal expansion
(tumor self-seeding) (49).
In CRC, cells can become insensitive to the tumor suppressive effect of TGFβ
due to the genetic inactivation of the TGFβ signaling pathway. This allows them to
over express TGFβ. This cytokine can induce the secretion of interleukin 11 from
stromal fibroblasts in the liver and facilitate the development of metastasis (50). Also,
stromal fibroblasts can generate hepatocyte growth factor that enhances Wnt/β-catenin
signaling to promote the stem cell potential of CRC cells (51).
1.3.3 Epithelial to Mesenquimal Transition (EMT)
EMT is a process where epithelial cells switch to a mesenchymal progenitor-cell phe-
notype, in which they de-polarize and become motile. Such transformation can be
induced by reactivation of developmental programs in cancer cells by certain cytokines
(52). Loss of E-cadherin is a requirement for EMT (53), and the pathways involved
in EMT include the TGFβ signaling pathway, the Wnt pathway and multiple tyrosine
kinase receptor pathways like fibroblast growth factor receptor, EGFR and platelet-
derived growth factor receptor (53). EMT transformation allows the cells to gain func-
tions that will favor metastasis, like stemness, motility and even resistance to therapy
9
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(54), although the role of EMT in metastasis has to be further defined. Transcriptional
regulators that promote EMT can both promote (55) and inhibit (56) metastatic col-
onization. Besides, metastasis usually show epithelial and not mesenchymal features.
A likely explanation is that EMT is a transient estate that allows cancer cells to dis-
seminate, but that has to be reverted by mesenchymal to epithelial transition (MET)
at the metastatic site (57).
1.3.4 Intravasation, Circulation and Extravasation
Cancer cells can enter the circulation until the primary tumor is removed. Tumors can
relesease cancer cells into the circulation in high numbers, as can be inferred from the
presence of circulating tumor cells found in the blood of cancer patients (58). Exper-
imental evidence using a mouse model of mammary tumors shows that macrophages
can facilitate tumor cells intravasation, even in the absence of local angiogenesis (59).
Once in the circulation, cells can be directed to specific organs depending on the site
of origin by circulation patterns (e.g. liver in the case of colon cancer cells entering the
mesenteric circulation). Surviving into circulation also requires the gaining of specific
traits (60), which usually happen by genetic changes ocurring in the primary tumor
(61). Finally, cancer cells have to be able to extravasate once they reach the distant
organ. Several genes that mediate the extravasation of cancer cells to the brain (62),
lungs (41, 63, 64, 65) and liver (64) have been described.
1.3.5 Colonization
Colonization is one of the main bottlenecks for metastasis formation. Colonization
refers to the following steps: survival on arrival, formation of micro metastasis, adoption
of latency, reactivation of growth, recirculation and even formation of tertiary lesions in
the same or different organs. Still, cancer cells die easily at distant sites due to reasons
not completely understood. Contributing factors can be the stress of passing through
endothelial barriers, exposure to the immune system in the distant organ and lack of
survival and proliferation signals in the host tissue.
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1.3.5.1 Survival on arrival
Most cells that infiltrate a distant organ do not survive. Specific traits have to be gained
by cancer cells in order to avoid exposure to lethal signals from the reactive stroma,
upregulate cell survival and antiapoptotic pathways. Survival on arrival depends on
a successful interaction with stromal elements like macrophages (66) and on gainig
certain functions like the gain of Src activity of breast cancer cells to be able to survive
on bone marrow (47).
1.3.5.2 Stemness
Cells that reach distant organs do not necessarily have the capacity to create metastasis;
to do so they must be able to recapitulate tumor growth. The term “metastatic stem
cell” (MSC) has been coined to refer to those cells that are able to reinitiate macroscopic
tumor growth in a distant organ. This “stemness” can be present already in the primary
tumor or can be gained through phenotypic plasticity once the MSC have left the
tumor of origin. The fact that MSC can be already present in the primary tumor is
supported by the following: (i) primary tumors that express a stem cell-like signature
are associated with poor prognosis and early distant relapse (67) and (ii) cells isolated
from primary tumors using stem cell markers can generate metastasis in animal models
(68). In the case of CRC, it has been demonstrated that metastasis arise from cells
with stem-like properties like long-term self-renewal capacity, quiescence and resistance
to chemotherapy (69, 70). Epigenetic changes (e.g. methylation) can drive EMT, a
stem-like featured that in this case can be gained once the cell has left the primary
tumor.
1.3.5.3 Metastatic Niches
As pointed out above, metastatic cells need to find a favorable environment (i.e.
stroma) to trhive. The term “metastatic niche” refers to the specific locations and
environments (extracellular matrix proteins, stromal cell types and diffusible signals)
that support the survival and self-renewal of metastatic cells. Three different sources
of metastatic niches have been proposed (71):
• Native stem cell niches, which refer to locations where the stem cells reside under
physiological conditions, like the intestinal epithelium, bone marrow, epidermis
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and brain (72, 73). Recent evidence shows that prostate cancer cells benefit from
an environment that enhances stem cells properties and metastasis in a native
stem cell niche in the bone marrow (74).
• Niche functions provided by stromal cells outside of native stem cell niches. An
example is the perivascular niche: cancer cells typically initiate growth around
blood capillaries. This tendency to settle in perivascular niches is true for glioma,
breast cancer, lung cancer and melanoma cells that infiltrate the brain (75, 76).
Cells proliferate around blood vessels, forming a multilayered sheath that remod-
els the capillary network and becomes the core of an expanding lesion (71). In
the case of brain metastasis, L1CAM -an adhesion molecule and marker of bad
prognosis- plays a key role in allowing cancer cells to settle in this niche location
(77). Beyond providing oxygen and nutrients, perivascular niches can stimulate
growth by paracrine factors. In the case of CRC, this happens via the expression
of Jagged-1 by the endothelial cells (78).
• Stem cell niche components that might be produced by the cancer cells them-
selves. Periostin and tenascin C (TNC) are examples of proteins produced by
cancer cells that contribute to distant spread. Tumor cells can produce TGFβ
that in turn recruits fibroblast that produce periostin which is required for the
initiation of lung metastasis by breast cancer cells in mice (79). TNC can be
expressed by breast cancer cells and regulates several factors that promote tumor
growth (Musashi, Notch and Wnt) and lung metastasis (80).
1.3.6 Cellular latency
“Metastatic latency” is a clinical term to denote the time elapsed from the primary
tumor diagnosis to the detection of overt metastases in imaging techniques. Differ-
ent primary tumors have metastatic latencies of different legths: it is usually long in
prostate cancer, sarcoma and melanoma, and short in lung and some breast cancers.
At the celular level this latency depends both on the equilibrium of cell proliferation
and cell death and on adoption of quiescent states by infiltrating cells (81). Entry in
G0 phase can be a defense under adverse conditions (82, 83). Other mediators of the
transition between dormancy and proliferation are p38 and ERK (mitogen activated
kinases) (84) as well as bone-morphogenetic proteins and their antagonists (85). This
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aspect of metastasis mechanisms biology is not as developed as others, probably in part
due to the difficulty to replicate long latencies in animal models.
1.4 Clinical Management
Clinical management of CRC is based in its classification into four stages (AJCC (86)
stages I to IV) according to the information provided by clinical examination and
imaging techniques. Initial diagnosis is usually done either by screening (i.e. screening
colonoscopy or occult fecal blood test) or driven by symptoms of the primary tumor
(e.g. anemia, gastrointestinal overt bleeding or gastrointestinal symptoms like changes
in bowel habit or even large bowel obstruction). Staging and treatment is different for
colon and rectal cancer.
1.4.1 Colon cancer
Clinical guidelines for the diagnosis and staging of colon cancer recommend the use of
colonoscopy, abdominal and pelvic computed tomography scans and pathologic exami-
nation of the surgical specimen for localized tumors (87, 88, 89). Chest CT scan is not
required (89, 90).
Stages I to III are considered as localized disease (absence of distant organ metas-
tasis), with five-year overall survival ranging from 65% to 95% (91). The mainstay of
treatment for stages I to III is surgical resection. Patients with a tumor that surpasses
muscularis propia in the bowel wall but without regional lymph node involvement after
an adequate evaluation (at least 12 lymph nodes) of the surgical specimen (i.e. stage
II) can be offered treatment with adjuvant (i.e. postoperative) fluorouracil modulated
with leucovorin. The benefits of this adjuvant therapy are modest. A trial that studied
a population with 91% of stage II patients (92) found a 3.6% absolute increase in in
overall survival (OS) at 5 years and no statistically significant benefit in OS among stage
II patients. Three meta-analysis failed to prove a benefit of adjuvant fluoropyrimidine-
based chemotherapy in stage II patients in terms of overall survival (93, 94, 95). As
opposed to treatment of stage III patients (see below), the addition of oxaliplatin to the
adjuvant chemotherapy regimen has proven of no benefit in stage II patients (91, 96).
The standard of care after resection of tumors with lymph nodes involvement and
absence of distant metastasis (i.e. stage III) is oxaliplatin in combination with flu-
13
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orouracil or capecitabine (91, 96). This regimen showed an statistically significant
increase in OS of 4% at 5 years (91) when compared with an adjuvant therapy based
solely in 5-FU.
In approximately 25% of the cases, CRC presents distant metastasis at diagnosis
(stage IV) and about 30% of the patients with localised stages will suffer from distant
metastasis during follow-up. Patients with metastasis have a median survival that
ranges from 6 to 20 months (97). The main prognostic factors of stage IV CRC patients
are the number, size and location of metastasis (which determine their resectability),
LDH levels and performance status (98).
Treatment of advanced CCR is based on palliative chemotherapy containing 5-
fluorouracil (or capecitabine) plus oxaliplatin or irinotecan. This can be complemented
with monoclonal antibodies directed against EGFR (cetuximab (99), panitumumab
(100)) for those patients with wild type KRAS and NRAS (100, 101). Other active
drugs approved for the treatment of stage IV patients include regorafenib (102) (an
orally active inhibitor of multiple angiogenic and non-angiogenic tyrosine kinases) and
aflibercept (103) (a protein consisting of VEGF binding portions from the human VEGF
receptors 1 and 2 that acts as a decoy receptor preventing pro-angiogenic efectors from
binding to their receptors). The benefit of adding any of these targeted therapies rarely
goes beyond an increment of 2 months in median OS. The role of bevacizumab, a mon-
oclonal antibody against the vascular endothelial growth factor, is not well stablished
since it has not proven to be effective in improving OS (97, 104).
The best way to combine and sequence all the approved drugs for metastatic CRC
to optimize treatment is not yet established.
1.4.2 Rectal cancer
The main difference between the management of colon and rectal cancer relies on the
local staging and local treatment, due to a higher propensity to local relapse in patients
with rectal tumors because of its location. Besides the imaging techniques enumerated
above for the staging of colon cancer, further local staging should be obtained with
endoscopic ultrasonography or preferably, with magnetic resonance imaging.
The standard of care of localized rectal cancer is preoperative concomitant chemo
and radiotherapy (105, 106) followed by surgery using total mesorectal excision (107).
The value of postoperative chemotherapy is not well established, specially for those
14
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patients that achieve a pathological complete response after preoperative chemo and
radiation (108). Treatment of metastatic rectal cancer does not substantially differ
from that of colon cancer (109).
15
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2Hypothesis
2.1 Hypothesis
• Germline variants can be associated with different patterns of invasion and or
distant metastasis of CRC.
• Given that the CRC-risk variant rs4939827 is associated with survival in patients
diagnosed with CRC, it may be differentially associated with CRC phenotypic
and/or molecular subtypes.
• Tumor-derived genetic changes can drive the patterns of invasion and/or metas-
tasis
• Cancer cells in stablished metastases can gain functions that allow them colonize
a new distant organ (i.e. metastasis from metastasis).
17
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3Objectives
1. To evaluate the association of the germline variant rs4939827 with CRC risk
according to specific clinical phenotypes and molecular characteristics.
2. To develop a murine model for colorectal metastasis and use it to enrich the
metastatic phenotype of CRC lines. Use the highly metastatic cell line to identify
novel mechanisms of invasion and/or metastasis
19
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4Publications
4.1 First publication
Phenotypic and tumor molecular characterization of colorectal cancer in
relation to a susceptibility SMAD7 variant associated with survival
Xabier Garcia-Albeniz, Hongmei Nan, Linda Valeri, Teppei Morikawa, Aya Kuchiba,
Amanda I. Phipps, Carolyn M. Hutter, Ulrike Peters, Polly A. Newcomb, Charles S.
Fuchs, Edward L. Giovannucci, Shuji Ogino and Andrew T. Chan
Carcinogenesis 2013 Feb;34(2):292-8. doi:10.1093/carcin/bgs335
4.1.1 Summary
The minor allele (G) of rs4939827 -an intronic variant of SMAD7 (18q21)- is associated
with a lower risk of developing CRC (OR of 0.88, 95% CI: 0.85 - 0.93)(23) and poorer
survival after diagnosis (HR of 1.16, 95% CI: 1.06-1.27)(25). We evaluated the associ-
ations of this variant with tumor phenotype and several molecular characteristics. We
used 1509 CRC cases and 2307 age-matched controls nested within the Nurses Health
Study (NHS) and the Health Professionals Follow-up Study (HPFS).
The NHS is a cohort initiated in 1976 with over 120,000 registered nurses. The
HPFS is a cohort initiated in 1986 with over 50,000 male health professionals. In
both cohorts information is updated biennially via questionnaires, with a follow-up
greater than 90%. Samples for DNA extraction (blood or buccal cell specimens) from
both cohorts were obtained in more than 90,000 individuals. Information on CRC is
extracted from medical records by study physicians after obtaining permission from
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participants who reported CRC in the biennial questionnaires. We randomly selected
between one and three controls (matched on ethnicity, year of birth and month/year of
sampling) within the same cohort from participants who were free of CRC at the same
time the CRC was diagnosed in the cases.
Among the 1509 cases with blood or buccal samples in this study, we were able to
successfully obtain tissue suitable for molecular analyses in 658 cases. We genotyped
rs4939827 (TaqMan R©) successfully in 98% of the samples in NHS and 99.6% of the
samples in HPFS. We used logistic regression to assess the association of rs4939827
with risk of CRC according to different phenotypic and molecular characteristics. The
phenotipic features evaluated were: TNM stage, grade of differentiation, location of the
primary tumor (colon vs. rectum) and age at diagnosis. The evaluated molecular char-
acteristics were DNA methylation of RUNX3 and LINE-1 (long interspersed nucleotide
element-1), CpG island methylator phenotype (CIMP), microsatellite instability, TP53
expression by immunohistochemistry and the mutational status of BRAF, KRAS and
PIK3CA. We adjusted significance hypothesis testing by multiple comparisons.
We modeled each SNP using a log-additive approach, relating genotype dose (i.e.
number of copies of the minor allele) to risk of CRC. We adjusted all analyses for age at
sample collection, race, gender, aspirin use, non-steroidal anti-inflammatory drugs use,
body mass index, physical activity, familial history of CRC, smoking, alcohol, meat
consumption, energy-adjusted calcium and folate intake and type of sample (blood
versus cheek). To assess heterogeneity in the association between rs4939827 and tumors
according to clinical phenotype or molecular characteristics, we used a case-case design
using logistic regression model comparing tumor subtypes.
We found that the minor allele (G) in rs4939827 was associated with a lower risk of
developing tumor stage pT1 or pT2 CRC [multivariate odds ratio (OR), 0.73; 95% con-
fidence interval (CI) 0.62-0.87] but not tumor stage pT3 or pT4 (multivariate OR, 1.07;
95% CI 0.93-1.23, P for heterogeneity = 1.2 x 10−4). The association between rs4939827
and CRC also significantly differed by methylation of RUNX3 (P for heterogeneity =
0.005). Among those with CRC, the minor allele (G) in rs4939827 was significantly
associated with poorer overall survival (hazards ratio, 1.20; 95% CI, 1.02-1.42).
We performed mediation analyses (110, 111) to decompose the total effect of the
exposure (rs4939827) on the outcome (T3-T4 tumors) into a “direct effect” plus an
“indirect effect” The “direct effect” can be interpreted as the OR comparing the risk
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of T3-T4 tumor stage with the genetic variant present vs. absent if the mediator (e.g.
RUNX3 ) were what it would have been without the genetic variant. The “indirect
effect” can be interpreted as the OR for T3-T4 tumor stage for those with the genetic
variant present comparing the risk if the mediator were what it would have been with
versus without the genetic variant (110).
The multivariate ORs that estimate the direct effect of rs4939827 were 1.96 (95%
CI 1.183.25, P-value = 0.009) for one variant allele and 4.46 (95% CI 1.1916.6, P-value
= 0.038) for two variant alleles. The multivariate ORs estimating the indirect effect of
rs4939827 on risk of pT3 and pT4 tumors was 1.05 (95% CI 0.961.15, P = 0.32) for
one variant allele and 1.50 (95% CI 0.445.10, P = 0.51) for two variant alleles. We did
not found evidence of neither multiplicative nor additive interaction between rs4939827
and RUNX3 methylation.
In conclusion, we found that the minor allele (G) of the germline intronic SMAD7
variant rs4939827 is associated with a lower risk of CRC with earlier tumor stage and
CRC without methylation of the tumor suppressor RUNX3. These findings suggest
that individuals with this SMAD7 variant that develop CRC are more probably to
have tumors with greater invasiveness and methylation of RUNX3, which potentially
contributes to their poorer observed survival.
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The minor allele (G) of rs4939827, a SMAD7 (18q21) intronic vari-
ant, is associated with a lower risk of developing colorectal cancer 
(CRC) and poorer survival after diagnosis. Our objective was to 
evaluate the associations of this variant with different tumor phe-
notype and intratumoral molecular characteristics. We evaluated 
1509 CRC cases and 2307 age-matched controls nested within 
the Nurses’ Health Study and the Health Professionals Follow-up 
Study. We used the TaqMan assay to genotype rs4939827 and 
logistic regression to assess the association of rs4939827 with 
risk of CRC according to different phenotypic and molecular 
characteristics. We found that the minor allele (G) in rs4939827 
(SMAD7, 18q21) was associated with a lower risk of developing 
tumor stage pT1 or pT2 CRC [multivariate odds ratio (OR), 
0.73; 95% confidence interval (CI) 0.62–0.87] but not tumor stage 
pT3 or pT4 (multivariate OR, 1.07; 95% CI 0.93–1.23, P for het-
erogeneity = 1.2 × 10−4). The association between rs4939827 and 
CRC also significantly differed by methylation of RUNX3 (P for 
heterogeneity = 0.005). Among those with CRC, the minor allele 
(G) in rs4939827 was significantly associated with poorer overall 
survival (hazards ratio, 1.20; 95% CI, 1.02–1.42). We can con-
clude that the minor allele (G) of the germline intronic SMAD7 
variant rs4939827 is associated with a lower risk of CRC with 
earlier tumor stage and CRC without methylation of the tumor 
suppressor RUNX3. These findings suggest that individuals with 
this SMAD7 variant that develop CRC are more probably to have 
tumors with greater invasiveness and methylation of RUNX3, 
which potentially contributes to their poorer observed survival.
Introduction
Genome-wide association studies (GWAS) have identified 20 colo-
rectal cancer (CRC) susceptibility variants, corresponding to 16 loci 
(1–8). One of the earliest identified and most consistently validated 
variants, rs4939827 (18q21.1), resides in an intronic region of the 
gene SMAD family member 7 (SMAD7), which is associated with 
the TGFB1 (transforming growth factor-β) pathway. The minor allele 
(G) in rs4939827 is associated with a lower risk of CRC, with the 
most recent GWAS observing an odds ratio (OR) of 0.88 [95% con-
fidence interval (CI) 0.85–0.93, P-value = 1.1 × 10−7] (9). Recently, 
in a pooled analysis of five prospective cohorts, we observed that 
the G allele is also associated with poorer survival [hazards ratio 
(HR) = 1.16, P-value = 0.02] (10). Based on these results, we hypoth-
esized that rs4939827 may be differentially associated with CRC sub-
types associated with worsened outcomes or are related to the TGFB1 
pathway, including methylation of RUNX3. Thus, we examined the 
association of rs4939827 with CRC risk according to specific clinical 
or molecular phenotypes within the Nurses’ Health Study (NHS) and 
the Health Professionals Follow-up Study (HPFS), two of the pro-
spective cohorts included in our prior analysis (10).
Materials and methods
Study population
The NHS was initiated in 1976, when 121 700 female USA registered nurses 
between the ages of 30 and 55 years returned a mailed health questionnaire. The 
HPFS was established in 1986 with a parallel cohort of 51 529 USA male den-
tists, pharmacists, optometrists, osteopath physicians, podiatrists and veterinar-
ians between the ages of 40 and 75 years. In both cohorts, we have subsequently 
updated information biennially with greater than 90% follow-up. In 1989–90, 
we collected blood samples from 32 826 participants in the NHS cohort. In 
1993–95, we collected blood samples from 18 159 participants in HPFS. The 
samples were collected in heparinized tubes and sent to us by overnight courier 
in chilled containers. In 2001–04, 29 684 women in NHS and 13 956 men in 
HPFS mailed in a ‘swish-and-spit’ sample of buccal cells. Participants who pro-
vided buccal cells had not previously provided a blood specimen. On receipt, 
blood and buccal cells were centrifuged, aliquoted and stored at −70°C.
In both cohorts, we requested permission to obtain medical records and 
pathology reports from participants who reported CRC on our biennial 
questionnaires. We identified fatal cases from the National Death Index and 
from next-of-kin (11). Study physicians blinded to exposure data reviewed 
all medical records to confirm cases of CRC. As described previously, we 
randomly selected between one and three controls within the same cohort from 
participants who were free of CRC at the same time the CRC was diagnosed 
in the cases (12). We matched controls with blood specimens (1013 in NHS 
and 673 in HPFS) to cases with blood specimens (483 in NHS and 372 in 
HPFS); similarly, controls with buccal specimens (423 in NHS and 198 in 
HPFS) were separately matched to cases with buccal specimens (439 in NHS 
and 215 in HPFS). Controls were matched to each case on ethnicity, year of 
birth and month/year of blood or buccal sampling (12). In total, 1509 (922 in 
the NHS and 587 in the HPFS) cases and 2307 (1436 in the NHS and 871 in the 
HPFS) controls were included in our analysis. The institutional review boards 
at Brigham and Women’s Hospital and the Harvard School of Public Health 
approved this study.
Genotyping
The SNP rs4939827 was genotyped by the 5′ nuclease assay (TaqMan®), using 
the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, 
Foster City, CA). TaqMan® primers and probes were designed using the 
Primer Express® Oligo Design software v2.0 (ABI PRISM). Laboratory per-
sonnel were blinded to case-control status, and 10% blinded quality control 
samples (duplicated samples) were inserted to validate genotyping procedures; 
concordance for the blinded quality control samples was 100%. Primers, 
probes and conditions for genotyping are available upon request. We success-
fully genotyped rs4939827 in 98% of samples in NHS and 99.6% of samples 
in HPFS. We confirmed that rs4939827 was in Hardy-Weinberg Equilibrium 
among the controls (χ2 P-values = 0.93 for NHS and 0.85 for HPFS).
Abbreviations:  BH, Benjamini and Hochberg; BMI, body mass index; 
CI,confidence interval; CIMP, CpG island methylator phenotype; CRC, 
colorectal cancer; GWAS, genome-wide association study; HPFS,Health 
Professionals Follow-up Study; HR,hazards ratio; LINE-1, long interspersed 
nucleotide element-1; MPE,molecular pathological epidemiology; MSI, 
microsatellite instability; MSS, microsatellite stable; NHS, Nurses’ Health 
Study;  NSAIDs, non-steroidal anti-inflammatory drugs; OR, odds ratio; 
RERI, relative excess risk due to interaction.
†These authors contributed equally to this work.
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Pathological assessment of molecular characteristics
Beginning in 1997 in the HPFS and 2001 in the NHS, we began retrieving, from 
the pathology departments of treating hospitals, available pathological speci-
mens from participants whom we confirmed had received a diagnosis of CRC 
up to 2006 (13). Among the 1509 cases with blood or buccal samples in this 
study, we were able to successfully obtain tissue suitable for molecular analy-
ses in 658 cases. Real-time PCR (MethyLight) was used for quantitative DNA 
methylation to determine CpG island methylator phenotype (CIMP) status using 
DNA extracted from paraffin-embedded tissue. We quantified DNA methylation 
in eight CIMP-specific promoters (including RUNX3) as detailed elsewhere (14). 
CIMP-high was defined as >6 of 8 methylated markers using the eight-marker 
CIMP panel, and CIMP-low/0 was defined as 0 of 8 to 5 of 8 methylated mark-
ers, according to the previously established criteria (15). Microsatellite insta-
bility (MSI) analysis was performed using 10 microsatellite markers (D2S123, 
D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67 and 
D18S487). MSI-high was defined as the presence of instability in >30% of the 
markers, and MSI-low/microsatellite stable (MSS) as instability in 0–29% of 
markers (15). Long interspersed nucleotide element-1 (LINE-1) methylation 
level was assessed by pyrosequencing using the PyroMark kit and the PSQ HS 96 
System (Qiagen, Valencia, CA). The average of the relative amounts of C in the 
four CpG sites evaluated was used as overall LINE-1 methylation level in a given 
sample (16). We performed PCR and pyrosequencing targeted for KRAS (codons 
12 and 13), BRAF (codon 600) and PIK3CA (exons 9 and 20 (15,17,18)). TP53 
expression was assessed by immunohistochemistry as detailed elsewhere (19).
Statistical analysis
We used logistic regression to estimate OR and corresponding 95% CIs for the 
association of variant rs4939827 with CRC among subgroups defined by tumor 
phenotype (T3-4 and T1-2; N1-2 and N0; M1 and M0; poorly differentiation and 
moderately well differentiation; rectum and colon location and age of diagnosis 
<60 and >60 years) and by molecular characteristics [RUNX3 promoter meth-
ylation and absence of methylation; KRAS mutant and wild type (WT); BRAF 
mutant and wild type; PIK3CA mutant and wild type; LINE-1 methylation-low 
and methylation-high; MSI-H and MSI-L/MSS]. We obtained similar results 
using unconditional or conditional logistic regression adjusting for matching 
factors (data not shown). Thus, we present unconditional regression models 
adjusting for matching factors and other known or suspected risk factors. The 
Cochran’s chi-square-based Q statistic test was used to assess the extent of het-
erogeneity across the two studies. Because there was little evidence for hetero-
geneity for the association of the SNP rs4939827 with CRC risk between women 
and men (P for heterogeneity = 0.32), we pooled data from the two studies.
We modeled each SNP using a log-additive approach, relating genotype 
dose (i.e. number of copies of the minor allele) to risk of CRC. We adjusted 
all analyses for age at sample collection, race, gender, regular aspirin use (yes 
or no), regular non-steroidal anti-inflammatory drugs (NSAIDs) use (yes or 
no), body mass index (BMI; in tertiles), physical activity (in tertiles), history 
of CRC in a parent or sibling (yes or no), smoking status (never, former or cur-
rent smoker), alcohol consumption (0–4.9, 5–9.9, 10–14.9 or ≥ 15.0 g per day), 
consumption of beef, pork or lamb as a main dish (0–3 times per month, once a 
week, 2–4 times per week or ≥5 times per week), energy-adjusted calcium and 
folate intake (in tertiles) and type of sample (blood versus cheek). To assess 
heterogeneity in the association between rs4939827 and tumors according to 
clinical phenotype or molecular characteristics, we used a case–case design 
using logistic regression model comparing tumor subtypes (20).
We performed mediation analyses as described in (21,22). In brief, this 
approach decomposes the total effect of the exposure (rs4939827) on the 
outcome (T3-T4 tumors) into a ‘direct effect’ plus an ‘indirect effect.’ The 
‘direct effect’ consists of the effect of rs4939827 on T-stage at a fixed level 
of the mediator variable [i.e. the direct effect can be interpreted as the OR 
comparing the risk of T3-T4 tumor stage with the genetic variant present 
versus absent if the mediator (e.g. RUNX3) were what it would have been 
without the genetic variant]. The ‘indirect effect’ is the effect on the outcome 
(T-stage) of changes of the exposure (rs4939827) that operate through the 
methylation status of RUNX3. (The indirect effect can be interpreted as the OR 
for T3-T4 tumor stage for those with the genetic variant present comparing 
the risk if the mediator were what it would have been with versus without the 
genetic variant.) This approach allows for the adjustment of covariates and for 
the presence of interaction between the variables of interest (21). We computed 
additive interaction in the form of relative excess risk due to interaction (RERI) 
using the delta method (23) and multiplicative interaction by entering a product 
term in the model and assessing its significance by the Wald method.
For analyses of rs4929827 in relation to survival, we confined the cohort 
to the 646 incident cases of CRC diagnosed after collection of blood or buc-
cal cells. We calculated the time from CRC diagnosis to death from CRC, 
death from any cause or the end of follow-up (1 June 2010), whichever came 
first. For CRC-specific survival, deaths from other causes were censored at 
the time of death. We used Cox proportional hazards regression to calculate 
HRs and 95% CI for the association between the SNP and survival, adjust-
ing for age, race, sex (cohort), tumor stage, grade of differentiation, regular 
aspirin use, smoking status at diagnosis, alcohol consumption, consumption 
of beef, pork or lamb as a main dish and energy-adjusted calcium and folate 
intake as described above. The proportional hazards assumption was verified 
by plotting the cumulative martingale residuals and assessing for significance. 
We corrected for multiple comparisons with several tumor subtypes using the 
Benjamini and Hochberg (BH) false discovery rate adjustment (24). We cor-
rected for the 14 assessed interactions; the values of the corrected P-values, 
when significant, are presented as footnotes in the tables. SAS V9.2 (SAS 
Institute, Cary, NC) was used for the analysis.
Table I.  Baseline characteristics of cases and controlsa
NHS (women) HPFS (men) Total
Cases Controls Cases Controls Cases Controls
(n = 922) (n = 1436) (n = 587) (n = 871) (n = 1509) (n = 2307)
Age at diagnosis [years, mean (SD)] 66.8 (9.2) 69.2 (9.2) 67.7 (9.3)
Age at sample draw (years, mean) 59.5 (6.6) 59.6 (6.5) 64.8 (8.5) 64.9 (8.4) 62.5 (8.2) 62.1 (7.9)
Non-white (%) 13 (1.4) 6 (0.4) 49 (8.4) 59 (6.8) 62 (4.1) 65 (2.5)
Regular aspirin use (%)b 324 (35.1) 656 (45.7) 269 (45.8) 450 (51.7) 593 (39.3) 1106 (47.9)
Regular NSAID drug use (%)c 303 (32.9) 570 (39.7) 136 (23.2) 190 (21.8) 439 (29.1) 760 (32.9)
BMI [kg/m2, mean (SD)]d 26.1 (5.1) 26.0 (5.0) 26.2 (3.3) 25.6 (3.3) 26.1 (4.5) 25.8 (4.5)
Physical activity [METs - h/week, mean (SD)]e 15.7 (14.3) 16.0 (14.0) 29.4 (24.2) 31.1 (25.2) 21.1 (20.0) 21.8 (20.5)
CRC in a parent or sibling (%) 212 (23.0) 239 (16.6) 114 (19.4) 132 (15.2) 326 (21.6) 371 (16.1)
Former or current smoker (%) 537 (59.0) 791 (55.0) 319 (60.0) 441 (55.0) 856 (59.0) 1232 (55.0)
Alcohol consumption [g/day, mean (SD)] 6.8 (10.2) 6.3 (9.4) 13.4 (15.7) 11.8 (13.2) 9.4 (13.1) 8.4 (11.3)
Beef, pork or lamb as a main dish [servings/week, 
mean (SD)]
2.8 (0.8) 2.8 (0.8) 2.7 (0.9) 2.6 (0.9) 2.7 (0.8) 2.7 (0.8)
Total calcium intake (mg/day, mean)f 952.4 (364.1) 1007.5 (386.9) 916.1 (399.4) 950.6 (382.5) 938.1 (378.7) 985.8 (386.2)
Total folate intake (µg/day, mean)f 426.8 (179.1) 447.8 (194.9) 526.0 (226.2) 566.2 (231.6) 465.9 (204.7) 492.9 (217.3)
aAt blood draw or cheek cell sampling. 
bRegular aspirin user was defined as the consumption of at least two 325 mg tablets per week in the NHS and at least two times per week in the HPFS. Non-
regular user was defined otherwise.
cRegular NSAID user was defined as the consumption of NSAIDs at least two times per week. Non-regular user was defined otherwise.
dThe BMI is the weight in kilograms divided by the square of the height in meters.
eMetabolic Equivalent  of Task (MET) denotes metabolic equivalent. Met (h) = sum of the average time/week in each activity × MET value of each activity. One 
MET, the energy spent sitting quietly, is equal to 3.5 ml of oxygen uptake per kilograms of body weight per minute for a 70 kg adult.
fNutrient values (calcium and folate) represent the mean of energy-adjusted intakes.
SMAD7 variant and colon cancer phenotype
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Results
Among our total study population of 1509 CRC cases and 2307 con-
trols, the minor allele (G) frequency for rs4939827 was 48.6%, con-
sistent with the HapMap CEU population. The baseline characteristics 
of the cases and controls are presented in Table I. Compared with 
controls, CRC cases in both women and men were less probably to 
have regularly used aspirin or NSAIDs, have a family history of CRC, 
were more probably to smoke, consumed higher amounts of alcohol 
and had lower intakes of calcium and folate. Among men, cases had 
a higher BMI and were less physically active. Among women, cases 
were less probably to have used postmenopausal hormones. Although 
the minor allele (G) of rs4939827 was not significantly associated 
with CRC in our total population, the trend was in the direction previ-
ously reported (multivariate OR, 0.93; 95% CI 0.84–1.04, P = 0.22).
We confirmed our prior findings relating rs4939827 with survival 
among cases of CRC (10). Among the 646 cases of CRC diagnosed 
after blood or buccal cell collection, we observed that the minor allele 
of rs4939827 was significantly associated with poorer overall survival 
(multivariate HR, 1.20; 95% CI 1.02–1.42, P  = 0.031) and a trend 
toward poorer CRC-specific survival (HR = 1.20, 95% CI 0.98–1.47, 
P = 0.08).
To determine if the survival difference we observed according 
to the G allele was related to a differential association with tumor 
phenotypes, we examined the influence of rs4939827 on CRC sus-
ceptibility according to traditional clinicopathological features in our 
total study population. The association of the G allele of rs4929827 
with CRC risk appeared to differ according to pT stage or the depth 
of invasion of the tumor (P for heterogeneity = 1.0 × 10−4). The G 
allele of rs4929827 was inversely associated with a risk of tumors 
staged as pT1 or pT2 (multivariate OR, 0.73; 95% CI 0.62–0.87, 
P-value = 2.8 × 10−4). In contrast, there was no association between 
rs4939827 and tumors staged as pT3 or pT4 (multivariate OR, 1.07; 
95% CI 0.93–1.23, P-value = 0.38). Hence, the prevalence of tumors 
Table II. Associations of rs4939827 with tumor phenotypesa
Controls Cases OR (95% CI) Cases OR (95% CI) Case-only analysis
pT1/pT2 pT3/pT4 pT3/pT4 versus pT1/pT2
TT 600 155 1 200 1 1
TG 1120 241 0.84 (0.65–1.10) 363 1.19 (0.93–1.53) 1.54 (1.10–2.15)
GG 538 95 0.51 (0.36–0.72) 182 1.14 (0.85–1.53) 2.31 (1.50–3.56)
P trend 2.8 × 10−4 0.38 1.0 × 10−4b
G allelec 0.73 (0.62–0.87) 1.07 (0.92–1.23) 1.52 (1.23–1.88)
N0 N1-2 N1-2 versus N0
TT 600 236 1 114 1 1
TG 1120 407 1.10 (0.87–1.38) 191 0.88 (0.65–1.20) 0.79 (0.55–1.14)
GG 538 190 0.84 (0.63–1.11) 81 0.71 (0.49–1.04) 0.83 (0.53–1.31)
P trend 0.27 0.08 0.36
G allele 0.93 (0.81–1.06) 0.85 (0.70–1.02) 0.90 (0.72–1.13)
M0 M1 M1 versus M0
TT 600 358 1 40 1 1
TG 1120 622 1.04 (0.85–1.27) 68 0.90 (0.56–1.44) 0.88 (0.54–1.44)
GG 538 287 0.84 (0.66–1.07) 26 0.70 (0.39–1.26) 0.78 (0.41–1.46)
P trend 0.20 0.24 0.43
G allele 0.93 (0.82–1.04) 0.84 (0.63–1.12) 0.88 (0.64–1.20)
Moderately or well-differentiated tumors Poorly differentiated tumors Poorly versus moder-
ately well differentiated 
tumors
TT 600 299 1 56 1 1
TG 1120 494 1.00 (0.81–1.24) 104 1.01 (0.66–1.54) 1.08 (0.68–1.69)
GG 538 235 0.85 (0.66–1.10) 50 0.95 (0.57–1.57) 1.28 (0.74–2.21)
P trend 0.23 0.84 0.39
G allele 0.93 (0.82–1.05) 0.98 (0.76–1.25) 1.13 (0.86–1.48)
Colon cancer Rectal cancer Rectum versus colon
TT 600 118 1 36 1 1
TG 1120 233 1.14 (0.86–1.52) 66 1.03 (0.65–1.64) 0.90 (0.55–1.49)
GG 538 90 0.84 (0.59–1.18) 28 0.83 (0.48–1.45) 0.88 (0.48–1.62)
P trend 0.36 0.54 0.66
G allele 0.92 (0.78–1.09) 0.92 (0.70–1.20) 0.93 (0.69–1.27)
Age of diagnosis >60 years Age of diagnosis <60 years <60 versus >60 years
TT 600 337 1 80 1 1
TG 1120 598 1.04 (0.85–1.28) 134 0.96 (0.65–1.40) 0.83 (0.52–1.33)
GG 538 263 0.83 (0.65–1.07) 67 0.95 (0.61–1.48) 1.19 (0.68–2.08)
P trend 0.18 0.81 0.63
G allele 0.92 (0.82–1.04) 0.97 (0.78–1.21) 1.07 (0.81–1.42)
aORs and P-values are adjusted for age at sample collection, race, gender, regular aspirin use, regular NSAIDs use, BMI, physical activity, history of CRC in a 
parent or sibling, smoking status, alcohol consumption, consumption of beef, pork or lamb as a main dish, energy-adjusted calcium and folate intake and type of 
sample (more details in the text). 
bBH-adjusted P-value = 0.0014.
cLog-additive model, representing the OR for each additional G allele as compared with TT.
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with pT3-4 stage was 65.7% for cases of CRC with two variant 
alleles, 60.1% for cases of CRC with one variant allele, compared 
with 56.3% for cases of CRC with no variant alleles of rs4939827 
(Mantel–Haenszel P-value = 0.018). The rs4939827 SNP was not sig-
nificantly differentially associated with any of other evaluated clinical 
and pathological phenotypes, including nodal status, presence of dis-
tant metastases, tumor grade, anatomic location and age at diagnosis 
(Table II).
We also examined rs4939827 genotype according to molecu-
lar subtypes among 658 cases for whom we had available tumor 
tissue data. Because rs4939827 is located in an intronic region 
of SMAD7, which modulates TGFB1 signaling, we evaluated 
rs4939827 according to promoter methylation of the RUNX3 gene, 
which is related to the TGFB1 pathway. The G allele of rs4939827 
was associated with a lower CRC risk in tumors without meth-
ylation of RUNX3 (multivariate OR, 0.84; 95% CI 0.71–0.99, 
P = 0.035). In contrast, there was a suggestive, although not sta-
tistically significant, increased risk of tumors with methylation of 
RUNX3 associated with the minor allele of rs4939827 (multivari-
ate OR, 1.27; 95% CI 0.94–1.74, P = 0.12) (Table III). The differ-
ence between rs4939827 and risk of tumors with methylation of 
RUNX3 compared with tumors without methylation of RUNX3 was 
statistically significant after adjustment for multiple comparisons 
(P for heterogeneity = 0.0053, BH-corrected P-value = 0.037). The 
risk of CRC associated with rs4939827 also appeared to be modi-
fied by BRAF mutational status. However, the P for heterogeneity 
was 0.021, non-significant after adjustment for multiple compari-
sons (BH-corrected P-value = 0.10). The association between the 
rs4939827 SNP and CRC did not significantly differ according to 
any of the other markers examined, including CIMP status, LINE-1 
methylation, KRAS mutation, PIK3CA mutation, MSI status and 
TP53 mutation.
RUNX3 methylation was associated with a higher risk of pT3 and 
pT4 tumors (multivariate OR, 2.12; 95% CI 1.18–3.80, P = 0.012) 
even after adjusting for rs4939827. The multivariate ORs estimating 
the indirect effect of rs4939827 on risk of pT3 and pT4 tumors was 
1.05 (95% CI 0.96–1.15, P  =  0.32) for one variant allele and 1.50 
(95% CI 0.44–5.10, P = 0.51) for two variant alleles (Table IV). Given 
the width of the CIs, we cannot exclude a possible indirect effect of 
rs4939827 through RUNX3 methylation on pT stage. The multivari-
ate ORs that estimate the direct effect of rs4939827 were 1.96 (95% 
CI 1.18–3.25, P-value = 0.009) for one variant allele and 4.46 (95% 
CI 1.19–16.6, P-value = 0.038) for two variant alleles. There was no 
evidence of interaction between the SMAD7 variant rs4939827 and 
RUNX3 methylation in either the additive scale (RERI = 0.48; 95% CI 
−1.42 to 2.37, P-value = 0.62) or multiplicative scale (OR, 0.93; 95% 
CI 0.39–2.19, P-value = 0.87).
Discussion
In this large study of 1509 cases of CRC and 2307 controls nested 
in two prospective cohorts, the CRC-susceptibility locus SMAD7 
intronic rs4939827 was associated with a lower risk of CRCs with 
pT1 and pT2 stage but not pT3 and pT4 stage. Hence, among indi-
viduals diagnosed with CRC, those with at least one G allele had 1.5-
fold higher odds of having a pT3 or pT4 tumor compared with a pT1 
or pT2 tumor. This finding may explain in part observed associations 
of the G allele of rs4939827 with lower overall risk of incident CRC 
(9), but worsened survival after diagnosis (10,25).
This study represents a strategy of investigations, which has been 
recently termed ‘molecular pathological epidemiology’ (MPE) 
(20,26). MPE is conceptually based on inherent heterogeneity of a 
disease, which is typically regarded as a single entity in traditional 
epidemiology studies, including GWAS (20,26). MPE can decipher 
how risk factors are associated with specific alterations in molecular 
pathways in cancer. Moreover, the MPE design can be used to help 
shed insight into the function of susceptibility variants identified by 
GWAS based upon their association with specific molecular subtypes 
of CRC (20).
The seemingly contrary associations of this SNP in SMAD7 with 
decreased risk of incident disease but poorer outcomes in patients 
with established disease may be due to SMAD7’s known involvement 
in modulating the TGFB1 pathway. In normal epithelium, TGFB1 
functions as a tumor suppressor through induction of cell arrest and 
inhibition of cell proliferation. However, once cells are resistant to 
TGFB1-mediated proliferative inhibition (i.e. in established tumors), 
TGFB1 appears to promote metastasis by enhancing angiogenesis 
and extracellular matrix disruption and inhibiting infiltrating tumor 
immune cells. A role for rs4939827 in the TGFB1 pathway is further 
supported by our findings of significant association of rs4939827 with 
RUNX3 methylation status in the tumors. RUNX3 is a Runt domain 
transcription factor 3 involved in TGFB1 signaling by interaction with 
SMAD transcription factors and is considered a suppressor of solid 
tumors. The RUNX3 promoter is commonly aberrantly methylated in 
a CpG island in CRC (27–29), leading to gene inactivation.
Differential methylation of RUNX3 according to rs498327 could 
plausibly explain the worsened survival among individuals with CRC 
who have a variant G allele (30). In addition to TGFB1, RUNX3 is 
involved in WNT regulation by forming a ternary complex with TCF4 
and CTNNB1 (β-catenin) (31). Both TGFB1 and WNT signaling 
are involved in the induction of epithelial-mesenchymal transition, 
a process that mediates invasion and metastasis in CRC. However, 
our mediation analysis does not suggest that the association between 
rs4939827 on risk of CRC according to pT stage is primarily related 
to RUNX3. Nonetheless, the mediation analysis should be interpreted 
in the context of some limitations (22), including the assumption of a 
lack of other, strong unmeasured confounders.
Previous studies of CRC-susceptibility variants and tumor pheno-
type have observed only a few significant differential associations 
between rs4939827 and CRC according to other clinical phenotype 
or molecular features. A case-only analysis of 1531 cases did not find 
any association between this variant and pT3-4 compared with pT1–
2-staged tumors (P = 0.94) (32). In a study of 1096 patients from the 
Epicolon I cohort  (33), the G allele of rs4939827 was significantly 
associated with well-differentiated tumors under a log-additive model 
(HR, 0.67; P-value = 0.027). However, this association was not repli-
cated in a validation cohort, EPICOLON II (34). Neither of these two 
studies found any association between rs4939827 and other tumor 
features, including grade of differentiation, stage or tumor site. On the 
other hand, two studies have observed that the G allele of rs4939827 
increased the risk of harboring a rectal tumor as compared with colon 
tumors (35,36).
We also examined several other molecular markers other than 
RUNX3 and did not observe strong differences in the association with 
rs4939827. Our findings are consistent with Slattery et al., who did not 
observe significant heterogeneity in associations of rs4939827 with 
CIMP status, MSI, KRAS or p53 mutational status (36). Nonetheless, 
in our study, it is notable that BRAF-status did appear to be differen-
tially associated with rs4939827, despite the lack of a significant P for 
heterogeneity after correction for multiple comparisons. An interplay 
between TGFB1 and BRAF mutations is biologically plausible (37), 
and BRAF mutations are strongly associated with CRC prognosis. 
Thus, given the low frequency of BRAF mutations in CRC, it is pos-
sible that statistically significant heterogeneity may be evident with a 
larger sample size.
Our study has several strengths. First, we used prospectively col-
lected, biennially updated, detailed data on CRC risk factors over 
long-term follow-up. This permitted us to account for the main poten-
tial confounders of our associations. Second, our case-control study 
was nested within two large well-characterized cohorts within which 
matched controls were selected from the same cohort from which the 
case developed, minimizing the likelihood of population stratification 
or selection bias. Third, our findings were consistent between two 
independent cohorts. Moreover, we have previously demonstrated a 
consistent association between rs498327 and CRC and overall sur-
vival that has been validated by results in other populations (10). 
Last, among a large number of participants, we had germline DNA as 
well as available tumor tissue to examine the expression of molecular 
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markers, including RUNX3, which is directly relevant to the TGFB1 
pathway. This permitted us to examine rs4939827 in relation to tumor 
subtypes with greater mechanistic specificity.
We acknowledge the limitations to our study. First, we did not have 
tumor specimens available for analysis for all of our cases. However, the 
risk factors in cases with available tumor tissue did not appreciably differ 
Table III. Association of rs4939827 with tumor molecular characteristicsa
Controls Cases OR (95% CI) Cases OR (95% CI) Case-only analysis
RUNX3 promoter unmethylated RUNX3 promoter methylated Methylation versus 
unmethylation
TT 600 142 1 25 1 1
TG 1120 254 1.07 (0.82–1.40) 63 1.40 (0.79–2.50) 1.43 (0.74–2.78)
GG 538 95 0.66 (0.47–0.94) 35 1.65 (0.87–3.12) 2.97 (1.39–6.35)
P trend 0.04 0.12 0.0053b
G allelec 0.84 (0.71–0.99) 1.27 (0.94–1.74) 1.74 (1.18–2.56)
WT BRAF Mutant BRAF Mutant versus WT BRAF
TT 600 162 1 19 1 1
TG 1120 286 1.05 (0.81–1.35) 41 1.09 (0.53–2.24) 1.86 (0.77–4.48)
GG 538 126 0.80 (0.58–1.09) 24 1.64 (0.75–3.58) 3.17 (1.19–8.47)
P trend 0.19 0.21 0.02
G allele 0.90 (0.78–1.05) 1.29 (0.86–1.93) 1.77 (1.09–2.88)
LINE-1 methylation-high LINE-1 methylation-low Methylation-high versus low
TT 600 108 1 67 1 1
TG 1120 210 1.23 (0.91–1.66) 115 0.92 (0.63–1.33) 0.80 (0.51–1.27)
GG 538 101 1.13 (0.80–1.60) 43 0.57 (0.35–0.93) 0.55 (0.31–1.00)
P trend 0.48 0.03 0.05
G allele 1.06 (0.90–1.26) 0.78 (0.62–0.98) 0.75 (0.56–1.00)
CIMP-low/negative CIMP-high CIMP-high versus low/
negative
TT 600 146 1 21 1 1
TG 1120 267 1.07 (0.82–1.40) 50 1.53 (0.78–3.00) 1.65 (0.76–3.59)
GG 538 108 0.76 (0.55–1.06) 24 1.41 (0.65–3.05) 2.27 (0.93–5.56)
P trend 0.15 0.40 0.07
G allele 0.89 (0.76–1.04) 1.17 (0.81–1.68) 1.50 (0.97–2.34)
MSI-L/MSS MSI-H MSI-H versus MSI-L/MSS
TT 600 159 1 21 1 1
TG 1120 268 1.00 (0.77–1.29) 54 1.63 (0.85–3.14) 1.93 (0.95–3.90)
GG 538 120 0.79 (0.58–1.08) 26 1.47 (0.70–3.09) 1.99 (0.87–4.55)
P trend 0.16 0.33 0.10
G allele 0.90 (0.77–1.04) 1.19 (0.84–1.68) 1.40 (0.94–2.07)
WT KRAS Mutant KRAS Mutant versus WT KRAS
TT 600 113 1 69 1 1
TG 1120 215 1.24 (0.91–1.67) 113 0.86 (0.60–1.22) 0.69 (0.44–1.09)
GG 538 93 0.94 (0.65–1.36) 55 0.77 (0.51–1.18) 0.87 (0.50–1.51)
P trend 0.85 0.23 0.51
G allele 0.98 (0.82–1.17) 0.88 (0.71–1.09) 0.91 (0.69–1.20)
WT PIK3CA Mutant PIK3CA Mutant versus WT PIK3CA
TT 600 139 1 31 1 1
TG 1120 251 1.07 (0.81–1.40) 57 0.94 (0.56–1.58) 0.85 (0.48–1.52)
GG 538 120 0.90 (0.65–1.25) 18 0.62 (0.31–1.23) 0.64 (0.30–1.37)
P trend 0.58 0.19 0.26
G allele 0.96 (0.82–1.12) 0.81 (0.58–1.11) 0.81 (0.56–1.17)
TP53 negative TP53 positive TP53 positive versus 
negative
TT 600 76 1 67 1 1
TG 1120 151 1.14 (0.81–1.61) 120 1.15 (0.78–1.69) 0.83 (0.50–1.39)
GG 538 66 0.86 (0.56–1.31) 51 0.84 (0.52–1.36) 0.81 (0.43–1.55)
P trend 0.54 0.56 0.50
G allele 0.94 (0.77–1.15) 0.93 (0.74–1.17) 0.90 (0.65–1.24)
aORs and P-values are adjusted for age at sample collection, race, gender, regular aspirin use, regular NSAIDs use, BMI, physical activity, history of CRC in a 
parent or sibling, smoking status, alcohol consumption, consumption of beef, pork or lamb as a main dish, energy-adjusted calcium and folate intake and type of 
sample (more details in the text).
bBH-adjusted P-value = 0.0371.
cLog-additive model, representing the OR for each additional G allele as compared with TT.
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from those in cases without tumor tissue (38). Second, although we did 
correct for multiple comparisons in our primary analyses, we cannot 
rule out the possibility that the associations we observed with rs4939827 
and tumor subtypes represent false-positive findings. However, the bio-
logical plausibility of our findings and the consistent association of this 
allele with CRC survival increase the likelihood that our observed asso-
ciations are true. Third, we did include some cases of CRC in which par-
ticipants provided DNA samples after diagnosis. However, for analyses 
of survival, we restricted our cohort to incident cases diagnosed after 
DNA was collected to minimize any effect of survival bias.
In summary, individuals with the rs4939827 CRC-susceptibility 
locus diagnosed with CRC tend to develop tumors with greater inva-
siveness (pT stage). Moreover, we also observed a differential associa-
tion of rs4939827 with RUNX3 methylation status, supporting an effect 
of rs4939827 or causal variants tagged by this SNP on carcinogenesis 
mediated through the TGFB1 pathway. These findings support pre-
sent understanding of the dual function of TGFB1/SMAD7 pathways 
in inhibiting early tumorigenesis yet facilitating metastasis. Taken 
together, these results could explain, at least in part, the lower risk of 
CRC associated with the G allele of rs4939827 yet poorer survival (10).
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4.2 Second publication
4.2 Second publication
Colon cancer cells colonize the lung from established liver metastases through
p38 MAPK signalling and PTHLH
Jelena Urosevic, Xabier Garcia-Albeniz (co-first author), Evarist Planet, Sebastian
Real, Maria Virtudes Cespedes, Marc Guiu, Esther Fernandez, Anna Bellmunt, Sylwia
Gawrzak, Milica Pavlovic, Ramon Mangues, Ignacio Dolado, Francisco M. Barriga,
Cristina Nadal, Nancy Kemeny, Eduard Batlle, Angel R. Nebreda and Roger R. Gomis.
Nature Cell Biology 2014 Jul;16(7):685-94. doi: 10.1038/ncb2977.
4.2.1 Summary
The metastatic pattern of advanced CRC is somehow homogeneous. Liver is the most
frequently affected organ, followed by the lung, peritoneum and bone. We studied
the mechanisms driving the metastatic spread in CRC, focusing in the MAPK path-
way. We developed in vivo a highly metastatic cell line using a KRAS -mutated cell line
(SW620) using an ortothopic xenograft mouse model. First we introduced in these cells
an expression vector for luciferase, which allowed us to monitor the kinetics of emer-
gence of liver metastatic lesions by quantitative bioluminescence imaging. The SW620
luciferase-expressing cells were inoculated into portal circulation of immunodeficient
mice via intrasplenic injection followed by splenectomy, in order to isolate cell popula-
tions that target the liver. Second, the SW620-derived liver metastasis were expanded
in culture and the resulting population (Liver Metastatic derivative, LiM1) were sub-
jected to a second round of in vivo selection, producing the LiM2 cell population that
showed a significant increase in liver and lung metastatic activity. As opposed to the
metastasis originating from the parental cell line that showed wide areas of necrosis,
the LiM2 cells showed a higher stromal response.
Comparative transcriptomic analysis identified 194 genes differentially expressed
between the parental and the highly metastatic cell line. This colon cancer metastatic
(CCM) gene set was contrasted against a cohort of 267 patients with stage I-III CRC,
and those genes that were upregulated were associated with shorter time to relapse.
We investigated the signaling pathways regulating the expression of our set of genes
with increased metastatic capacity. Using KEGG annotated signaling pathways, we
found pathways of nitrogen metabolism, cell adhesion molecules and mitogen-activated
31
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protein kinases (MAPKs). These three pathways are relevant in the metastatic pro-
cess by mediating nucleotide synthesis, invasion/migration and modulation of cellular
responses respectively. We focused on the MAPKs given the KRAS -mutated status
of our cell line (and because patients harboring certain mutations in KRAS/BRAF
have fewer therapeutic options that patients without them), finding that the activating
phosphorylation of ERK1/ERK2 was increased, the p38 MAPKs was reduced and the
phosphorylation of JNKs did not change. Downregulation of ERK2 (but not of ERK1)
in the highly metastatic cell line reverted its metastatic capacity to the liver, but not
to the lung in our mice model. We thus hypothesized that the ability to metastasize
the lung by the highly metastatic derivative had to be driven by other mechanism.
The analysis of clinical samples evidenced that tumor biopsies with low phospho-38
MAPK were associated with metastasis to the lung but not to other organs. Treating
mice harboring liver metastasis from the parental cell line with a p38 MAPK specific
inhibitor produced an increase in the percentage of mice with lung metastasis. We
validated this increased capacity to generate lung metastasis with the inhibition of
phospho-38 MAPK using a different cell line (HCT116) and a different experimental
setting (mice intracecum injection). Conversely, activation of the p38 MAPK pathway
by expression of MKK6EE (MKK6 is a MAP kinase-kinase that phosphorylates and
activates p38 MAP kinase) diminished the lung metastatic capacity of the HCT116 cell
line. Of note, inhibition of phospho-38 MAPK did not affect proliferation or apoptosis.
The expression of parathyroid hormone-like hormone (PTHLH) was upregulated
(3.3 fold) in our highly metastatic derivative and was inversely correlated with the ex-
pression of MKK6 in CRC primary tumors. Downregulation of PHTLH in the highly
metastatic derivative decreased its capacity to colonize the lung without decreasing
its capacity to colonize the liver after intra porta inoculation. Interestingly, tail vein
(draining directly to the lungs) injections of the highly metastatic derivative did not
yield any lung metastasis and silencing PHTLH in LiM2 cells did not affect its growth
when injected directly into the lung. This suggested that the role of PTHLH in regu-
lating lung metastasis did not depended on growth promotion but more probably on
extravasation. This was supported by an experiment where we injected in the tail vein
LiM2 cells overexpressing or not PTHLH and quantified extravasation 48 hours later.
Mice injected with LiM2 cells overexpressing PTHLH presented a five-fold increase in
the number of cells extravasated in the lungs.
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4.2 Second publication
We finally evidenced that PTHLH induced apoptosis of human pulmonary endothe-
lial cells (HPEC) by increasing Ca+ levels that in turn induces mobilization of the
apoptosis-inducing factor mitochondrion-associated 1 (AIFM1), from the mitochondria
to the cytosol, a caspase-independent cell death mechanism. This disrupts the lung
vasculature increasing the permeability of the lung to metastatic cells.
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Colon cancer cells colonize the lung from established
liver metastases through p38 MAPK signalling
and PTHLH
Jelena Urosevic1,8, Xabier Garcia-Albéniz1,2,8, Evarist Planet1, Sebastián Real1, María Virtudes Céspedes3,4,
Marc Guiu1, Esther Fernandez1, Anna Bellmunt1, Sylwia Gawrzak1, Milica Pavlovic1, Ramon Mangues3,4,
Ignacio Dolado1,7, Francisco M. Barriga1, Cristina Nadal2, Nancy Kemeny5, Eduard Batlle1,6, Angel R. Nebreda1,6
and Roger R. Gomis1,6,9
The mechanisms that allow colon cancer cells to form liver and lung metastases, and whether KRAS mutation influences where
and when metastasis occurs, are unknown. We provide clinical and molecular evidence showing that different MAPK signalling
pathways are implicated in this process. Whereas ERK2 activation provides colon cancer cells with the ability to seed and colonize
the liver, reduced p38 MAPK signalling endows cancer cells with the ability to form lung metastasis from previously established
liver lesions. Downregulation of p38 MAPK signalling results in increased expression of the cytokine PTHLH, which contributes to
colon cancer cell extravasation to the lung by inducing caspase-independent death in endothelial cells of the lung
microvasculature. The concerted acquisition of metastatic traits in the colon cancer cells together with the sequential colonization
of liver and lung highlights the importance of metastatic lesions as a platform for further dissemination.
Colorectal cancer (CRC) metastasis follows an ordered and
hierarchical pattern. CRC cells initially spread to the lymph nodes
and peritoneal area. When metastases to the liver occur, a substantial
number of patients develop also lung and less frequently bone or
brain metastases1. Patients with metastasis are treated with systemic
chemotherapy, mostly in a palliative manner. Nevertheless, in selected
patients with isolated liver metastasis, increased 5 year survival can
be achieved by multimodal treatment that includes combination of
surgery with modern chemotherapy2. However, only about 25% of
patients can benefit from this type of treatment and the presence of
metastases in other organs is, in most cases, a contraindication for
resection3. After liver, lung is the most frequently involved organ4,5,
which highlights the need to understand mechanisms of CRC lung
metastasis to further improve disease control. The metastatic pattern
in CRC could be partially explained by the fact that the gut-draining
mesenteric vein together with the splenic vein forms the portal
system that drains directly into the liver. Beyond this simplistic
anatomical interpretation, mechanisms that regulate intravasation,
survival in portal circulation, infiltration and colonization of the
liver are also likely to contribute to the propensity of CRC metastasis
for the liver6. In addition, there is no explanation for why liver
metastasis is accompanied by lung colonization only in some patients.
Interestingly, CRC patients who underwent primary tumour resection
show a different pattern of relapse depending on theKRASmutational
status7. In particular, KRAS-mutated CRC has a higher incidence
of lung metastasis. This phenomenon suggests a KRAS-linked
mechanism that favours targeting of colon tumour cells to the lungs8.
RESULTS
An experimental model of colon cancer metastasis
To investigate the hierarchical mechanisms of liver and subsequent
lung metastasis in KRAS-mutated CRC, we established an orthotopic
xenograft mouse model to select for human CRC cells with enhanced
ability to colonize the liver and the lungs9,10. We focused on the human
colon adenocarcinoma cell line SW620, which harbours theKRASG12V
mutation. First, we introduced in these cells an expression vector for
1Institute for Research in Biomedicine (IRB Barcelona), 08028 Barcelona, Spain. 2Institut de Malalties Hemato-Oncològiques, Hospital Clínic de Barcelona-IDIBAPS
and CIBER-EHD), 08036 Barcelona, Spain. 3Grup d’Oncogenesi i Antitumorals, Hospital de Sant Pau, 08026 Barcelona, Spain. 4Grup d’Oncogenesi i Antitumorals,
Institute of Biomedical Research (IIB Sant Pau), Network Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08026 Barcelona,
Spain. 5Memorial Sloan-Kettering Cancer Center, 10065 New York, USA. 6Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
7Molecular Partners AG, 8952 Schlieren, Switzerland. 8These authors contributed equally to this work.
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luciferase, which allowed us to monitor the kinetics of emergence
of liver metastatic lesions by quantitative bioluminescence imaging.
The SW620 luciferase-expressing cells (parental) were inoculated into
the portal circulation of immunodeficient mice through intrasplenic
injection followed by splenectomy, to isolate cell populations that
target the liver (Fig. 1a). The initial SW620-derived liver metastasis
cells were expanded in culture and the resulting population (Liver
Metastatic derivative, LiM1) was subjected to a second round of
in vivo selection, producing the LiM2 cell population that showed a
significant increase in liver metastatic activity (Fig. 1a–d). Within 10
weeks post inoculation of LiM2 cells, 15 out of 18mice developed liver
metastasis as opposed to 6 out of 18 injectedwith parental SW620 cells,
suggesting that LiM2 cells acquired the ability to survive and adjust
to the liver environment (Fig. 1b–d). Besides the increased ability to
form livermetastasis, LiM2 cells also showed increased lungmetastatic
activity compared with parental SW620 cells (Fig. 1c,e), whereas
peritoneal metastasis and ascites production were observed at lower
but comparable rates in the two populations (Fig. 1c). Histological
examination revealed that, in most cases, liver metastatic lesions
derived fromLiM2 cells developed stromal response, as opposed to the
typical necrotic lesions derived from parental SW620 cells (Fig. 1d).
Interestingly, LiM2 cells showed an increased invasive capacity in
vitro compared with parental cells, suggesting the potential gain
of metastatic features (Supplementary Fig. 1a). Furthermore, LiM2
cells also showed enhanced liver and lung metastatic capabilities
in orthotopic mouse xenografts, whereas primary tumours grew
similarly to the parental cell population, indicating that proliferation
was not enhanced in LiM2 cells by the in vivo selection protocol
(Supplementary Fig. 1b–d).
Deregulated MAPK signalling in colon cancer cells is
associated with metastatic capacity
To investigate the molecular basis for aggressive concerted liver and
lung metastatic behaviour of KRAS-mutated CRC cells, we performed
transcriptomic analysis of the LiM2 and parental SW620 cell
populations. Comparative genome-wide expression analysis yielded a
list of 194 genes that were overexpressed or underexpressed at least
2.5-fold in the highly liver metastatic derivative LiM2 (Fig. 2a and
Supplementary Table 1). This group of genes showed a concordant
trend of regulation in metastatic derivatives and was named the
colon cancer metastatic (CCM) gene set. We divided the CCM set
of genes in two groups depending on whether their expression was
upregulated or downregulated, and performed a cross-validation in a
combined expression data set of 267 stage I–III clinically annotated
human primary CRC tumours from three independent institutions
(combined GSE17537 and GSE14333) (refs 11–13). The outcome
of interest was time to recurrence after primary tumour retrieval.
Using gene set enrichment analysis14 (GSEA), we found a strong
association between the upregulated CCM gene set and an increased
risk of recurrence (hazard ratio, HR) on treatment (false discovery rate
<1×10−6) (Fig. 2b). In contrast, the downregulated CCMgene set was
not found to be significantly associatedwith reduced risk of recurrence
(Supplementary Fig. 2a). Similar conclusions were obtained using
GSE17537 andGSE14333 expression data sets independently. Survival
analysis establishing subgroups by the median expression of the
upregulated CCM gene set also revealed that this gene set was
associated with reduced time to recurrence (Fig. 2b). Patients in the
combined GSE17537 plus GSE14333 cohort with higher expression
of the CCM gene set had an increment of 120% in the rate of
recurrence along time (HR = 2.20, 95% CI 1.22–3.98, P = 0.007).
Stage- and study-adjustedmultivariate analysis yielded aHR of similar
magnitude (HR = 1.88, 95% CI 1.04–3.36, P=0.037) supporting the
independent predictive capacity of the upregulated CCM gene set.
The integration of different oncogenic hits into particular signalling
pathways and cellular functions is key to understand how the
expression of groups of genes is collectively changed in metastatic cell
populations. Thus, we investigated the signalling pathways predicted
to regulate the expression of genes associatedwith increasedmetastatic
capacity of LiM2 cells. By using BGSEA (ref. 14), we found several
pathway-specific gene expression signatures (KEGG gene sets) that
were differentially represented in the gene expression profiles of
parental and LiM2 cells (Fig. 2c and Supplementary Table 2). These
included the pathways of nitrogen metabolism, which supports
nucleotide synthesis, cell adhesion molecules, which are fundamental
for invasion and migration, and mitogen-activated protein kinases
(MAPKs), which are important modulators of cellular responses15
(Supplementary Table 2). We focused our attention on MAPK
signalling alterations given the KRAS-mutated status of our initial
CRC cell population. We analysed the activation status of the three
main MAPK pathways in LiM2 cells and found that the activating
phosphorylation of ERK1/ERK2 was increased, whereas that of p38
MAPKs was reduced (Fig. 2d and Supplementary Fig. 2b) and the
phosphorylation of JNKs did not change (Fig. 2d). Significantly,
when the relative levels of phosphorylated (active) ERK2 and ERK1
were compared, we found that phospho-ERK2 levels were specifically
increased over phospho-ERK1 in CRC tumour biopsies from patients
that developed metastasis within 2 years post-surgery compared with
healthy mucosa from the same patients (distance from the tumour
>10 cm) or to CRC tumours of patients free of metastasis (Fig. 2e).
In 6 out of 7 primary tumours from CRC patients that developed
metastasis, the phospho-ERK2/phospho-ERK1 ratio was above 1,
whereas only 3 out of 13 non-metastatic CRC primary tumours had
higher phospho-ERK2 than phospho-ERK1 levels (Fig. 2e, P=0.036).
Furthermore, in a set of 20 healthy mucosa samples obtained from
the same patients as the CRC primary tumours, phospho-ERK2
levels were roughly equal to those of phospho-ERK1 in 80% of the
samples similarly to non-metastatic CRC primary tumours (Fig. 2e).
Next, we investigated the implication of the p38 MAPK pathway,
which was downregulated in LiM2 cells, and found that the reduced
levels of phosphorylated (active) p38 MAPK correlated with the
downregulation of MKK6 (MAP2K6), a key activator of p38 MAPKs
(ref. 16; Fig. 2f). Notably, in CRC primary tumours (pooled GSE17537
and GSE14333; n = 267 including stages I, II and III), MKK6
messenger RNA expression levels were inversely associatedwith a high
probability of relapse in the patients (Fig. 2g). These results support
that high phospho-ERK2 and low phospho-p38 MAPK activities are
associated with risk of metastasis in CRC patients.
ERK2 mediates colon cancer metastasis to the liver
Given that lung and liver metastatic events are co-selected in CRC
patients (Supplementary Table 3), particularly bearingKRAS-mutated
tumours, we wondered whether concerted changes in signalling
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Figure 1 Isolation and characterization of liver metastatic derivatives
from SW620 KRAS-mutated colorectal cancer (CRC) cells. (a) Schematic
representation of in vivo selection and isolation of liver metastatic
derivatives. (b) Liver-metastasis-free survival of mice injected intrasplenically
with SW620 poorly metastatic (parental) or highly metastatic (LiM2)
cells. n= 18 mice (pooled from two independent experiments) used per
cell line. Log-rank test was used to determine statistical significance.
(c) Percentage of liver metastasis, lung metastasis, peritoneal metastasis
and ascites in mice on intrasplenic injections of SW620 parental
and LiM2 cells determined post-mortem. Results were obtained using
18 mice (n) per cell line, and two-sided Fisher’s exact test was used
to calculate statistical significance. (d) Representative bioluminescent
images and photographs of livers, and haematoxylin and eosin (H&E)
and GFP staining of the liver sections. Scale bars, 500 µm. H, healthy
tissue; T, tumour; *, necrotic area. (e) Representative bioluminescent
images of lungs, and H&E and GFP staining of the lung sections from
mice injected intrasplenically with SW620 parental and LiM2 cells.
Scale bars, 500 µm.
pathways might be responsible for lung and liver colonization. Thus,
we next evaluated the contribution of each MAPK signalling pathway
to KRAS-mutated CRC liver and lung metastasis. As ERK2 activation
was increased in primary tumours of patients that developed
metastases, we downregulated the expression of ERK2 or ERK1 in
LiM2 cells bymeans of two independent short hairpin RNAs (shRNAs;
Fig. 3a and Supplementary Fig. 3a) Importantly, ERK2-knockdown
significantly decreased the capacity of LiM2 cells to colonize the liver
on intrasplenic injection into nude mice (Fig. 3a,b) whereas ERK1-
knockdown had no effect (Supplementary Fig. 3b). Of note, neither
ERK2 nor ERK1 depletion caused significant differences in orthotopic
tumour growth, proliferation or apoptosis (Supplementary Fig. 3c–e).
Interestingly, ERK2, but not ERK1, has been proposed to regulate,
through changes in expression of the transcription factors FRA1 and
ZEB1, a set of epithelial to mesenchymal transition responses in breast
cancer cells17, which has been associated with metastatic behaviour6.
We confirmed that high FRA1 expression levels were associated
with relapse in the combined colon cancer primary tumour gene
expression cohort described above (Supplementary Fig. 3f). These
results support that ERK2 signalling drives liver metastasis in KRAS-
mutated CRC cells.
p38 MAPK signalling mediates colon cancer metastasis to
the lung
Unexpectedly, ERK2 downregulation did not affect the capacity of
KRAS-mutated CRC cells to colonize the lungs (Fig. 3b). Thus, we
reasoned that lung colonization was controlled by an independent
mechanism. The p38 MAPK pathway has been implicated in several
pro and anti-tumorigenic functions15 and we found that human
fresh CRC tumour biopsies with low phospho-p38 MAPK levels
were associated with metastasis to lung but not to other tissues
(Supplementary Fig. 4a). To test the potential contribution of this
pathway toCRCmetastasis to the lung,we used the p38MAPKspecific
inhibitor PH-797804 (ref. 18). Parental cells were implanted directly
into the liver of nude mice (one implant per mouse) and, when liver
tumour photon flux signal reached a certain value (>108 photons s−1),
mice were randomly allocated to daily systemic treatment with either
vehicle or PH-797804 (Fig. 3c). Fifteen days post treatment, an
increase in lungmetastatic events was observed in PH-797804-treated
mice, whereas liver tumour growth was similar in both groups of
mice (Fig. 3c). Histological analysis confirmed p38 MAPK inhibition
in PH-797804-treated mice (Fig. 3c). As an alternative experimental
setting to test the implication of the p38 MAPK pathway in liver and
lung metastasis from the primary colon tumour, we used HCT116
cells. These KRAS-mutated CRC cells have the ability to form liver
and lung metastasis when implanted orthotopically in nude mice as
opposed to SW620 parental cells, which mainly produced lymph node
metastasis19 (Supplementary Fig. 1). We generated two derivatives
of HCT116 cells expressing either shRNA to downregulate p38α
(Fig. 3d), the most abundant p38 MAPK family member, or MKK6EE
to constitutively activate the p38 MAPK pathway16. The two cell
populations together with parental HCT116 cells were implanted
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Figure 2 Liver metastatic derivatives from SW620 KRAS-mutated CRC cells
present changes in MAPK signalling pathways. (a) Heat map representing
differential gene expression pattern between parental and LiM2 cells,
using 2.5-fold change as a cutoff. 114 genes were found upregulated
(yellow) and 80 downregulated (blue) in LiM2 compared to parental cells.
(b) Gene set enrichment analysis (GSEA; top) and Kaplan–Meier plot
(bottom) representing association of HR of recurrence with the upregulated
CCM gene set in the human colon cancer data set (pooled GSE17537
and GSE14333; n=267). NES, normalized enrichment score; FDR, false
discovery rate; HR, hazard ratio. (c) KEGG analysis representing signalling
pathways differentially represented in parental and LiM2 cells. (d) Left:
Western blot of phosphorylated ERK1/2, p38 and JNK MAPKs (P-ERK1/2,
P-p38, P-JNK) in SW620 parental and LiM2 cells. Total protein levels
of ERK1/2, p38 and JNK were analysed. Tubulin was used as a loading
control. Right: Quantification of phosphorylated ERK1/2, p38 and JNK
MAPKs normalized to total amount of the same proteins. n=9 (ERK1/2),
n= 10 (p38) and n= 6 (JNK) biological replicates pooled from at least
three independent experiments. Plots represent average plus s.d. *P<0.05;
**P<0.001; NS, not significant. (e) Top: Levels of phosphorylated ERK1/2
(P-ERK1/2) and total ERK1/2 proteins were analysed in samples of 20
primary CRC tumour samples (T) and their respective healthy mucosa (H)
by western blotting and representative blots are shown. The dashed lines
separate representative patient samples spliced from different gels. Bottom:
Ratio of P-ERK2/P-ERK1 normalized to total amount of protein in samples of
CRC tumours determined by western blotting; n=7 tumours with metastasis,
n=13 tumours without metastasis, n=20 healthy mucosa. Statistics: two-
tailed Mann–Whitney test; the box: 25th–75th percentile where the black
line within the box represents the median; whiskers: 10th–90th percentile.
(f) Association of MKK6 mRNA levels with the ratio of phosphorylated p38
(P-p38) protein levels in CRC tumours from n=20 patients. Plots represent
average plus s.d. (g) Kaplan–Meier curves representing the proportion of
recurrence-free patients stratified according to MKK6 mRNA levels in CRC
patient samples (pooled GSE17537 and GSE14333; n=267). Statistical
analysis was done using Cox proportional hazard’s model in b and g, and two-
tailed Student’s t-test in d and f. Uncropped images of blots are shown in
Supplementary Fig. 8.
orthotopically into the caecum, intestinal wall, of nude mice and 4
months later the mice were euthanized and primary tumours and
metastatic lesions to the liver and lungswere quantified.Nodifferences
in proliferation and apoptosis rates in the primary tumours were
detected among the groups (Supplementary Fig. 4b). Histological
analysis of the number and area of liver metastasis showed no
significant differences between control and p38α-knockdown cell
populations, whereas the percentage of mice with liver metastasis was
decreased in the latter group (Supplementary Fig. 4c,d). Interestingly,
HCT116 cells with reduced levels of p38α showed a significantly
higher capacity to colonize the lungs (Fig. 3d). Conversely, activation
of the p38 MAPK pathway by expression of MKK6EE markedly
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Figure 3 MAPK pathways mediate liver and lung metastasis in CRC. (a) Top:
Normalized ex vivo liver photon flux of mice injected intrasplenically with
LiM2 cells expressing control shRNA or two different ERK2 shRNAs. Bottom:
ERK2 downregulation was confirmed by western blot analysis; n=18 (Control
shRNA), n=10 (ERK2 shRNA1) and n=7 (ERK2 shRNA2) mice used in each
group pooled from two independent experiments. Statistical significance was
calculated using two-tailed Mann–Whitney test; the whiskers extend from
min. to max. of 1.5 interquartile range (Tukey box plot). (b) Percentage
of mice intrasplenically injected with LiM2 cells expressing the indicated
shRNAs that developed liver metastasis (top) or lung metastasis (bottom).
Representative bioluminescent images of livers and lungs are shown; n,
number of mice used in each group is stated in a; statistical significance was
calculated using two-sided Fisher’s exact test. NS, not significant. (c) Top:
SW620 parental cells were injected intra-liver and when lesions reached a
size of >108 photons s−1, mice were randomly separated into groups for two-
week treatment with vehicle (n=6) or the p38 MAPK inhibitor PH-797804
(n=6). Ex-vivo liver and lung photon flux of the 2 groups of mice together
with representative bioluminescent images of lungs are shown. One-sided
chi-squared test was used to calculate statistical significance. The whiskers
extend from the 10th to 90th percentile. Bottom: Western blot analysis of
P-p38 MAPK and p38α protein levels in metastatic lesions on two-week
treatment with vehicle or PH-797804. Tubulin was used as a loading control.
(d) Left: Western blot analysis of P-p38 MAPK and p38α levels in HCT116
cells infected with lentivirus expressing the indicated shRNAs. HCT116
cells expressing p38α shRNAs or constitutively active MKK6EE were injected
orthotopically into mice caecum, and the number of lung foci and the ratio
between the number of lung and liver foci was determined. n=5 (Mock), n=5
(MKK6EE) and n=4 (p38α shRNA) mice that developed lung metastasis in
each group. #P=0.043, †P=0.031 indicate statistical significance between
the groups. Statistical significance was calculated using one-tailed Mann–
Whitney test. In a and c the box extends from the 25th to 75th percentile
and the black line within the box represents the median. Uncropped images of
blots are shown in Supplementary Fig. 8. Representative western blot images
in a and d from three independent experiments.
reduced the ability of HCT116 cells to colonize the lungs, without
changing the liver colonization capacity (Fig. 3d and Supplementary
Fig. 4c,d) Collectively, these results suggest that the p38 MAPK
pathway negatively regulates the ability of KRAS-mutated CRC cells
to metastasize to the lung without affecting liver colonization.
p38 MAPK signalling controls PTHLH expression in metastatic
colon cancer cells
Next we investigated the mechanism by which p38 MAPK signalling
may drive lung metastasis from a previously established liver
metastasis. First, we excluded any differences in apoptosis rates of
metastatic emerging colonies due to variations in p38 MAPK activity
in HCT116 or SW620 cell derivatives (Supplementary Fig. 4e,f).
Next, we focused on genes under the control of this pathway
that could potentially interact with the liver or lung stroma to
trigger lung colonization. Among the genes that correlated with
MKK6 expression levels in CRC primary tumours (p< 0.05) and
whose expression changed at least 1.7-fold in metastatic LiM2
over parental SW620 cells, the parathyroid hormone-like hormone
(PTHLH) captured our attention as a gene that was upregulated
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Figure 4 p38 MAPK pathway controls the expression of PTHLH cytokine.
(a) Left: Venn diagram showing the overlap between genes that are
differentially expressed in parental and LiM2 cells (cutoff 1.7), orange
group, and genes that correlate significantly with MKK6 expression in CRC
primary tumour set GSE14333 (stages II and III), green group. Right: PTHLH
and MKK6 Spearman correlation in CRC primary tumours (GSE17537 and
GSE14333; n= 267). (b) qRT–PCR analysis of PTHLH mRNA levels in
CRC primary tumours that developed or did not develop metastases; n=8
tumours with metastasis and n=15 tumours without metastasis. The box
extends from the 25th to 75th percentile and the black line within the
box represents the median; the whiskers extend from the 10th to 90th
percentile. (c) mRNA and protein levels analysis of PTHLH in SW620 parental
and LiM2 cells. n= 3 values per group from independent experiments.
Plots represent average plus s.d. (d) mRNA and protein levels of PTHLH in
extracts of HCT116 cells infected with lentivirus expressing the indicated
shRNAs. n=3 values per group for mRNA studies and n=4 values per
group for protein studies. Each value is obtained in independent experiments.
Plots represent average plus s.d. (e) mRNA and protein levels of PTHLH
in SW620 parental and HCT116 cells treated with the indicated doses of
the p38 MAPK inhibitor PH-797804. n=4 (SW620 parental) and n=3
(HCT116) for mRNA studies. n=3 values per group for protein studies.
Each value is obtained in an independent experiment. Plots represent
average plus s.d. Statistical analysis was done using two-tailed Student’s
t-test in b–e.
(3.3-fold) and capable of conducting cancer cell–stroma interactions
(Fig. 4a and Supplementary Table 4). The association of high PTHLH
expression levels with metastatic relapse was confirmed in the
combined primary tumour gene expression cohort described above
(Supplementary Fig. 5a). We further validated the association of high
risk of metastasis with increased levels of PTHLH in an independent
set of 23 CRC tumour samples, including normal mucosa from the
same patients (Fig. 4b). Previous reports have implicated PTHLH
in endochondral bone development and epithelial–mesenchymal
interactions20,21 although, so far, it has never been associated with lung
metastasis. Importantly, PTHLH was upregulated not only in highly
metastatic LiM2 cells but also in p38α-knockdown HCT116 cells and
in p38 MAPK inhibitor treated SW620 parental and HCT116 cells
(Fig. 4c–e and Supplementary Fig. 5b,c).
PTHLH as mediator of lung metastasis extravasation
To test the implication of PTHLH in lungmetastasis ofKRAS-mutated
CRC cells, we downregulated PTHLH protein in highly metastatic
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Figure 5 PTHLH controls CRC metastasis to the lung. (a) Left: Liver-
metastasis-free survival curve of mice injected intrasplenically with LiM2
cells infected with lentivirus expressing control shRNA or PTHLH shRNA
and with cells in which PTHLH shRNA was combined with exogenous
expression of PTHLH (rescue). Right: Ex vivo lung photon flux in mice
injected intrasplenically with the above mentioned cell lines; n=19 (control
shRNA), n= 10 (PTHLH shRNA) and n= 10 (rescue) number of mice
used in each group pooled from two independent experiments; for ex vivo
lung photon flux statistics was calculated using one tailed Mann–Whitney
test. NS, not significant. (b) Left: Normalized liver ex vivo photon flux
on intrasplenic injections of SW620 parental cells either mock infected
or infected with a retrovirus that expresses PTHLH. Percentage of lung
metastasis in mice that developed liver metastasis on intrasplenic injection
of the indicated cells; n=6 (mock) and n=5 (overexpressing (OE) PTHLH)
number of mice used in each group. Right: Representative bioluminescent
images of liver and lung metastatic lesions. (c) Left: Lung-metastasis-free
survival on tail vein injections of control LiM2 cells (mock) or PTHLH-
expressing LiM2 cells (OE PTHLH). n=9 (mock) and n=7 (OE PTHLH)
mice used in each group. Right: Representative bioluminescent images
of mice at days 0 and 76 on injection and representative H&E staining
of lung sections are shown. Scale bar, 500 µM. (d) Lung-metastasis-free
survival on tail vein injections of PTHLH-expressing LiM2 cells treated with
PBS, PTHLH-neutralizing antibody (+NAb) or antagonist PTHLH peptide
(+AP). n= 8 (PBS), n= 8 (AP) and n= 8 (NAb) number of mice used
in each group. (e) Average number of cells found per lung section 48h
after tail vein injection of LiM2 cells either mock infected or overexpressing
PTHLH. Four 30 µm distant sections per animal were counted. n=16 (mock)
and n=20 (OE PTHLH) total number of sections counted per group. In
a,b and e the box extends from the 25th to 75th percentile and the
black line within the box represents the median; whiskers: 10th to 90th
percentile. Statistics: a left, c and d log-rank test; b and e two-tailed
Mann–Whitney test.
LiM2 cells (Supplementary Fig. 5d). We found that PTHLH-deficient
LiM2 cells were not significantly affected in liver metastatic activity
(Fig. 5a) but had decreased ability to form lung metastasis in
mice (Fig. 5a). On the other hand, PTHLH downregulation did
not affect the growth of LiM2 cells directly implanted in the lung
parenchyma of nude mice, indicating a possible role for PTHLH
in the process of lung metastatic extravasation (Supplementary
Fig. 6a,b). Importantly, PTHLH overexpression sufficed to provide
SW620 parental cells with the ability to efficiently colonize lungs from
the liver irrespectively of p38 MAPK activity levels (Fig. 5b). We
reasoned that a constant and continuous release of PTHLH from an
established liver metastasis could be necessary for priming the lung
before colonization. Consistent with the idea that distant preparation
of the niche might precede colonization, LiM2 cells were not able to
colonize the lung when delivered to the mice through the tail vein
(Supplementary Fig. 6c). Interestingly, LiM2 cells overexpressing large
quantities of PTHLH were capable of lung colonization when injected
into mice through the tail vein bypassing the requirement for the
existence of a pre-established liver metastatic lesion (Fig. 5c). This
was dependent on PTHLH because interfering with this cytokine,
by systemic administration of either a neutralizing antibody or an
antagonist peptide, impaired the lung colonization process (Fig. 5d).
As this experimental model is largely dependent on the extravasation
capabilities of metastatic cells and no significant differences were
observed in invasion, survival and migration functions, we tested
the contribution of PTHLH to cancer cell extravasation at the lung.
LiM2 cells overexpressing or not PTHLH, were injected through the
tail vein and mice were euthanized 48 h later. Subsequently, lungs
were extracted and the amount of cells extravasated into the lung
parenchyma was determined. This experiment showed a fivefold
increase in the number of cells detected per lung section in mice
injected with PTHLH-overexpressing LiM2 cells (Fig. 5e). Similar
results were obtained using an in vitro surrogate assay based on the
migration of LiM2 cells through a monolayer of endothelial cells
(Supplementary Fig. 7a).
To understand how the PTHLH released from tumour cells
supports extravasation, tight monolayers of human pulmonary
endothelial cells (HPMEC), which express the PTHLH receptor
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Figure 6 PTHLH induces caspase-independent death of human lung
vasculature endothelial cells. (a) Left: HPMEC cells were grown until reaching
tight confluence and then were treated with SW620 parental, LiM2, LiM2
control shRNA and LiM2 PTHLH shRNA cells conditioned medium for 24h.
Next, phalloidin (red) and DAPI (blue) stainings were performed. Gaps that
are formed in the monolayer on conditioned media treatment are indicated
with arrowheads and delineated with dashed lines. Scale bar, 200 µm. Right:
Total gap area and number of gaps per field were determined. Results
represent three independent experiments where each sample was seeded
in duplicate and at least ten fields per coverslip were analysed (gap area:
n=64, 85, 86 and 77 fields per group were analysed, respectively; and gap
number: n=63, 85, 66 and 78 fields per group were analysed, respectively).
Statistical significance was calculated using two-tailed Student’s t-test; the
box extends from the 25th to 75th percentile and the black line within the box
represents the median; the whiskers extend from the 10th to 90th percentile.
(b) Annexin V flow cytometry analysis of HPMEC cells treated for 4 h with
the indicated concentrations of PTHLH. (c) Average number of TUNEL-
positive endothelial cells in lungs 4 h post tail vein injection of recombinant
PTHLH (1–34). At least four 30 µm distant sections per animal were counted.
PBS (n=47 sections; 10 mice), 1 nM rPTHLH (n=48 sections; 10 mice),
0.01 nM (n=20 sections; 5 mice), 0.1 nM (n=20 sections; 5 mice), 10 nM
(n=30 sections; 5 mice), and 100nM (n=30 sections; 5 mice). Statistical
significance was determined using two-tailed Mann–Whitney test. All values
are presented in the graphs together with average ±s.d. (d) Annexin V
flow cytometry analysis of HPMEC cells treated for 4 h with the indicated
doses of PTHLH. Before PTHLH addition, some cells were pretreated for
2 h with the Z-VADfmk caspase inhibitor. In b and d numbers indicate the
average percentages of Annexin-V-positive (apoptotic) cells obtained from
three independent experiments where each sample was done in duplicate
(n = average of 6 replicates ±s.d.).
(PTH1R) (Supplementary Fig. 7b), were treated for 24 h with
conditioned media from parental and LiM2 cells or PTHLH-deficient
LiM2 cells. We found that only the media from cells expressing high
levels of PTHLH (LiM2 cells media, 0.02± 0.003 nM PTHLH) caused
a disruption of the HPMEC monolayer, suggesting that PTHLH
induced cell death (Fig. 6a). We corroborated PTHLH contribution
to this effect by pre-treatment of the conditioned media with a
PTHLH antagonist peptide, which prevented the PTHLH-induced
disruption of the HPMEC monolayer (Supplementary Fig. 7c).
Next, we confirmed by Annexin V staining in vitro and TUNEL
staining in vivo that recombinant PTHLH (1–34) was able to induce
HPMEC apoptosis in a dose-dependent manner (Fig. 6b,c and
Supplementary Fig. 7d). Interestingly, HPMEC apoptosis induced by
PTHLH was neither affected by the caspase inhibitor Z-VADfmk
(Fig. 6d) nor resulted in PARP or caspase-3 and caspase-7 cleavage
(Supplementary Fig. 7e), suggesting that the process was caspase-
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Figure 7 PTHLH induces Ca2+-dependent death of human lung vasculature
endothelial cells. (a) Relative fluorescence of Fluo4-AM calcium indicator
was determined in the course of 9 min. Cells were treated with control
medium at 2min and with medium containing 1.25 µM PTHLH at 5min . All
values were normalized to the lowest value obtained in the first two minutes
(basal level). Results represent the average of three independent experiments.
(b) Left: Representative images from three independent experiments of
AIFM1 localization in HPMEC cells treated for 4 h with PTHLH. Arrowheads
indicate cytosolic AIFM1. Scale bar, 114 µm. Right: Percentage of cells with
cytoplasmic AIFM1 from three independent experiments. Each condition
was done in duplicate and a total of 10 fields per condition were scored
(n= 30 fields per group). Statistical significance was determined using
two-tailed Mann–Whitney test. (c) Mice were injected in the tail vein with
LiM2 cells mock infected or infected with retrovirus expressing PTHLH.
Two days later, rhodamine dextran was injected. Representative image
of staining is presented. Scale bar, 12.5 µm. Vascular permeability was
measured by determining the average area of rhodamine dextran per lung
section using ImageJ software. Eight sections per mouse were analysed.
n=32 (mock) and n=40 (OE PTHLH) total number of sections analysed
per group. (d) Mice were injected in the tail vein with LiM2 cells treated
with or without recombinant PTHLH. Four hours later, rhodamine dextran
was injected and vascular permeability was measured by determining the
average area of rhodamine dextran per lung section using ImageJ software.
Four sections were analysed per mouse and 5 mice per group were used
(n=20 sections per group). Statistical analysis in c and d was done using
two-tailed Student’s t-test. (e) Schematic representation of p38 MAPK
and PTHLH implication in lung metastasis by CRC cells. The box in
b,c and d extends from the 25th to 75th percentile and the black line
within the box represents the median; whiskers extend from the 10th to
90th percentile.
independent. Consistent with this possibility, levels of proapoptotic
(Bak and Bid) and anti-apoptotic (Bcl-xl andMcl-1) proteins were not
changed on PTHLH treatment (Supplementary Fig. 7f).
PTHLH induces Ca2+-dependent death of endothelial cells of
the lung
Previous studies indicated that increased intracellular Ca2+ levels
can lead to cell death independently of both caspases and Bcl-2
family members22,23. In addition, PTH1R belongs to a group of
G-protein-coupled receptors, which on ligand binding can increase
Ca2+ levels in the cytosol24. Indeed, we found that PTHLH
treatment increased Ca2+ levels in HPMEC cells (Fig. 7a and
Supplementary Video 1). Next, we focused on the apoptosis-inducing
factor mitochondrion-associated 1 (AIFM1, also known as AIF),
a mitochondrial protein that is thought to play a central role in
caspase-independent cell death25,26 and that is released from the
mitochondria when cytosolic Ca2+ levels increase22,23. Interestingly,
we observed AIFM1 translocation from the mitochondria to the
cytosol on PTHLH treatment (Fig. 7b and Supplementary Fig. 7g). In
summary, PTHLH can trigger Ca2+ release and AIFM1 mobilization
leading to caspase-independent endothelial cell death, which, in
turn, destabilizes the vasculature increasing permeability at the lung
metastatic site (Fig. 7c,d). Collectively, these results support that p38
MAPK signalling downregulation couples lung and liver metastasis in
KRAS-mutant CRC cells through the control of PTHLH expression.
The release of PTHLH either from established liver lesions or
from metastatic cells trapped at the lung vasculature is likely to
increase lung endothelial permeability and facilitate metastatic cells
extravasation (Fig. 7e).
DISCUSSION
Our analysis of clinical samples indicates that high levels of ERK2
activity probably drive liver metastasis, whereas low p38 MAPK ac-
tivity further accounts for the capacity to colonize the lung (Fig. 7e).
Moreover, our findings emphasize the ability of the cytokine PTHLH
to trigger caspase-independent cell death at the lung vasculature as
a previously unrecognized contributor to the hierarchical process of
metastasis by facilitating the seeding of the lungs by KRAS-mutated
CRC cells growing in liver metastatic lesions. Previous studies have
implicated PTHLH in breast and squamous cell carcinoma tumour
progression to bonemetastasis through its activity in the bone remod-
elling process27–29. Our work illustrates the systemic contribution of
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PTHLH released from tumour cells in supporting distant metastatic
processes by triggering vascular permeability, and provides an expla-
nation for the enhanced expression of PTHLH reported in CRC tissue
compared with normal colorectal mucosa or polyps30. Moreover, our
results suggest that genetic changes that allow the primary metastasis
to the livermust be followed by additional genetic alterations that allow
secondary metastases from the liver to the lung, which emphasizes
the concept of metastases from metastases. We provide evidence for a
distinct mechanism that relies on different signalling pathways whose
hierarchicalmodulation enhances the ability of departing tumour cells
to consecutively seed the liver and the lungs (Fig. 7e). The obser-
vation that liver and lung colonization is linked to tumour-specific
or circulating cell-specific factors may create opportunities for the
development of targeted therapies to prevent disease dissemination
from the colon to the liver, and subsequently to the lungs. 
METHODS
Methods and any associated references are available in the online
version of the paper.
Note: Supplementary Information is available in the online version of the paper
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Cell culture. The SW620 colorectal cell line was obtained from ATCC. Cells were
transduced with retrovirus expressing the triple-fusion reporter gene encoding
herpes simplex virus thymidine kinase 1, GFP and firefly luciferase31. GFP-
expressing cells were sorted and maintained in 5% CO2 at 37 ◦C in DMEMmedium
(Gibco) supplemented with 5% fetal bovine serum (FBS) (Biological Industries),
0.29mgml−1 glutamine (Biological Industries), 100Uml−1 penicillin (Biological
Industries) and 0.1mgml−1 streptomycin (Biological Industries).
The HCT116 cell line was maintained in DMEM culture medium (Gibco)
supplemented with 10% fetal bovine serum (FBS; Biological Industries),
0.29mgml−1 glutamine (Biological Industries), 100Uml−1 penicillin (Biological
Industries) and 0.1mgml−1 streptomycin (Biological Industries). Clonetics HPMEC
cell line was from Promo Cell and was maintained in Endothelial Cell Growth
Medium MV2 (Promo Cell). PTHLH (1–34) recombinant protein (H-6630),
(Asn 10, Leu 11, D-Trp 12-PTHLH (7–34) amide antagonist peptide (no. H-3274),
rabbit anti-PTHLH (1–34) IgG (no. T-4512) and Z-VADfmk (no. n1560) were
purchased from Bachem.
Hyperactivation of the p38 MAPK pathway in HCT116 cells was achieved by
stable transfection of MKK6EE cloned into pCDNA3.1(+) using Fugene 6 (Roche),
followed by treatment with 100–200 µgml−1 hygromycin (Invitrogen) for 2 weeks or
until death of the non-transfected control. Mock cells were transfected with empty
pCDNA3.1(+) and subjected to the same procedure.
Lentiviral production. 293T cells were used for lentiviral production. Lentiviral
vectors expressing shRNAs against human PTHLH, MAPK1 (ERK2), MAPK3
(ERK1) and MAPK14 (p38α) from Mission shRNA Library were purchased from
Sigma-Aldrich. Transfection of 293T cells with lentiviral vectors was done using
standard procedures and viral supernatant was used for infection of SW620 cells.
Selection was done using puromycin (2 µgml−1) for 48 h. As a negative control in all
of the infections, lentivirus with non-target shRNAwas used (catalogue no. SHC016-
1EA).
PTHLH shRNA1 clone ID TRCN0000083846; sequence: 5′-CCGGCCAAGATT
TA CGGCGACGATTCTCGAGAATCGTCGCCGTAAATCTTGGTTTTTG-3′.
PTHLH shRNA2 clone ID TRCN0000083847; sequence:5′-CCGGCCCGTCC
GA TTTGGGTCTGATCTCGAGATCAGACCCAAATCGGACGGGTTTTTG-3′.
ERK1 shRNA1 clone ID TRCN0000006150; sequence: 5′-CCGGCCAAGATTT
ACGGCGACGATTCTCGAGAATCGTCGCCGTAAATCTTGGTTTTTG-3′.
ERK1 shRNA2 clone ID TRCN0000006152; sequence: 5′-CCGGCTATACCAA
GTCCATCGACATCTCGAGATGTCGATGGACTTGGTATAGTTTTT-3′.
ERK2 shRNA1 clone ID TRCN0000010050; sequence: 5′-CCGGTATCCATTCA
GCTAACGTTCTCTCGAGAGAACGTTAGCTGAATGGATATTTTT-3′.
ERK2 shRNA2 clone ID TRCN0000010040, sequence: 5′-CCGGCAAAGTTC
GAGTAG CTATCAACTCGAGTTGATAGCTACTCGAACTTTGTTTTT-3′.
p38α shRNA clone ID TRCN0000010051, sequence: 5′-CCGGGTTACGTGTG
GCAGTGAAGAACTCGAGTTCTTCACTGCCACACGTAACTTTTT-3′.
Animal studies. The institutional Animal Care and Use Committee of IRB
Barcelona approved all animal work. BALB/c nude female mice (Harlan) of 6–8
weeks of age were used for all studies.
For intrasplenic injections, animals were anaesthetized with a mixture of
ketamine (80mg kg−1) and xilacine (8mg kg−1) and 3 × 106 cells resuspended
in 100 µl of cold PBS were injected as previously reported32. On injection, cells
were allowed for 2min to pass from the spleen and enter the liver through the
portal circulation and next splenectomy was performed. Tumour development was
followed twice a week by bioluminescence imaging using the IVIS-200 imaging
system from Xenogen. Quantification of bioluminescent images was done with
LivingImage 2.60.1 software. For livermetastasis both ventral images of the abdomen
and dorsal images of the upper right side of themice back were quantified. All values
were normalized to those obtained at day 0. For metastasis-free survival curves,
metastatic events were scored when the measured value of either abdominal or
dorsal bioluminescence bypassed the value of day 0. On necropsy, the development
of metastasis was confirmed by performing ex vivo liver and lung bioluminescent
images as well as in histological sections. For tail vein injections 1×106 cells were
resuspended in 200 µl of cold PBS and injected into the tail vein. Lung tumour
development was followed once a week by bioluminescence imaging taking a photo
of the upper dorsal region that corresponds to the lung position. Quantification
of bioluminescent images was performed with LivingImage 2.60.1 software. All
obtained values were normalized to those obtained at day 0. For lung-metastasis-
free survival curves, metastatic events were scored when the measured value of
bioluminescence bypassed that of day 0. In Fig. 5d, before tail vein inoculation of
LiM2-overexpressing PTHLH cells, those were treated with PBS, PTHLH antagonist
peptide (AP) ((Asn 10, Leu 11, D-Trp 12)-PTHLH (7-34; Bachem); (5 µgml−1)
and PTHLH-neutralizing antibody (Nab; rabbit anti PTHLH (1–34) IgG; Bachem;
5 µgml−1). Next, cells were injected through the tail vein andmicewere continuously
treated with PBS or PTHLH AP (6 µg per dose, intraperitoneum injection) twice a
day or PTHLH NAb (6 µg per dose, intraperitoneum injection) once a day. Lung
metastasis was scored as described above.
Orthotopic injections were done as previously described33. Lung injections were
done using 5× 105 cells that were resuspended in 25 µl of cold PBS mixed with
25 µl of growth factor reducedMatrigel (BD Biosciences, no. 354230). Animals were
anaesthetized with a mixture of ketamine (80mg kg−1) and xilacine (8mg kg−1). A
small incision was made in the skin on the left side of the back of the mouse, level
with the lungs, and cells were injected into the lung using a 25G needle. For intraliver
injections animals were anaesthetized with a mixture of ketamine (80mg kg−1) and
xilacine (8mg kg−1). A small incision in the skin and peritoneum was made in the
liver area and liver lobules were gently removed. Injections were done using insulin
syringes (29Gx1/2 needle) and each mouse was injected with 5×105 cells that were
resuspended in 25 µl of cold PBSmixed with 25 µl of growth factor reducedMatrigel
matrix (BD Biosciences). Liver tumour development was followed once a week
by bioluminescence imaging, taking a photo of the ventral region. Quantification
of bioluminescent images was performed with LivingImage 2.60.1 software. Once
the tumour signal reached an established threshold (>108 photons s−1), mice
were randomly allocated to daily oral treatment with 10mg kg−1 of p38 inhibitor
PH-797804 (Selleckchem, no. S2726) or vehicle (0.5% methylcellulose and 0.025%
Tween 20 in PBS) for two weeks. For extravasation assays CellTracker Green (Life
Technologies, no. C7025)-marked cells (5×105) were resuspended in 200 µl of cold
PBS and injected into the tail vein. Forty eight hours later mice were perfused by
heart with 5ml of PBS and euthanized. The lungs were removed, the trachea was
perfused and these were fixed in formalin. Paraffin-embedded lungs were sectioned
and analysed.
For the in vivo lung permeability assay, 5 × 105 cells marked with 5 µM
CellTracker Green (Life Technologies) were resuspended in 200 µl of cold PBS and
injected into the tail vein. Two days after mice were injected intravenously with
rhodamine dextran (Mr 70K, Life Technologies, no. D1841) at 2mg per 20 g of body
weight and 3 h later mice were perfused by heart with 5ml of PBS and euthanized.
The lungs were extracted, the trachea was perfused and these were fixed in formalin.
Paraffin-embedded lungs were sectioned and analysed.
In addition, lung permeability was tested on injection of PBS or 10 nM (0.08 µg in
100 µl of PBS) recombinant PTHLH (1–34) through the tail vein. Of note, the molar
concentration of rPTHLH was adjusted to 2ml of the total mouse blood volume.
Four hours later, mice were injected intravenously with rhodamine dextran (Mr 70K,
Life Technologies) at 2mg per 20 g of body weight and 3 h later mice were perfused
by heart with 5 ml of PBS and euthanized. The lungs were extracted, the trachea was
perfused and these were fixed in formalin. Paraffin-embedded lungs were sectioned
and analysed.
For scoring of apoptotic cells in lungs, liver and ovary, PBS and indicated
concentrations of rPTHLH were injected through the tail vein of mice. Four hours
later mice were euthanized, and tissues were extracted and fixed in formalin.
Isolation of liver metastatic derivatives. Tumour formation on intrasplenic
injections was followed by bioluminescence imaging (see above). Mice were
euthanized when they presented the first signs of cachexia. Liver metastatic
lesions were localized by ex vivo bioluminescence imaging and resected under
sterile conditions. The lesions were minced and placed in culture medium
containing a mixture of DMEM and Ham F-12 (GIBCO) (1:1) supplemented with
0.125% collagenase III and 0.1% hyaluronidase. Samples were incubated at room
temperature for 4–5 h, with gentle rocking. After collagenase treatment, cells were
briefly centrifuged, resuspended in culturemedium and allowed to grow. GFP+ cells
were sorted for further propagation in culture or for inoculation in mice.
Gene expression profiling. RNA was extracted from cells using the RNeasy mini
kit (Qiagen). Labelling and hybridization of the samples to the HG1.0ST gene
expression chip (Affymetrix) were performed by the Functional Genomics Core
Facility of IRB Barcelona using standard methodology. Data analysis was performed
using R (Bioconductor). Quantile normalization and RMA summarization were
used to obtain probe set level expression estimates as implemented in the ‘oligo’
package of Bioconductor34. Both box plot and MA plots were checked before and
after normalization. To prevent nonspecific or mis-targeted probe sets biasing the
gene level expression estimates, for each gene we selected the 50% of the probe
sets with the highest inter-quartile range across all samples and obtained a gene
level expression estimate through median polishing, in a fashion analogous to
RMA. Class comparison of differential expression between parental and LiM2 cells
was performed with a linear-model-based moderated t-test as implemented in the
lima package. The t-test statistics were used to obtain a posterior probability for
differential expression following the semi-parametric empirical Bayes procedure35.
The posterior expected false discovery rate was set at 0.05. A heat map was used
to plot the expression of genes on a colour scale. A Euclidean distance metric was
used to compute the distance matrix of the gene expression levels and hierarchical
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clustering using a complete agglomeration method was used. Ranks of the data were
used for setting the colour scheme.
GSEA analysis.GSEA analysis was done as implemented in the phenoTest package
of Bioconductor.
BGSEA analysis. Gene set enrichment was assessed through Bayesian
enrichment36. We generated 1,000 posterior samples for the differential expression
indicator, according to the posterior probabilities of differential expression obtained
from pairwise comparisons. For each gene set we computed the probability of
enrichment as the proportion of posterior samples for which the percentage
of differentially expressed genes in the set was larger than the percentage of
differentially expressed genes in the rest of the genome.
MKK6 gene expression correlation. Gene expression data of stage II and III
patients of theGSE14333 humanCRCcohort were used. A Spearman correlation test
was performed for each gene againstMKK6 (MAP2K6). We corrected for multiple
testing using the Benjamini and Hochberg method37.
Migration assay. Cells were marked with 5 µM CellTracker Green (Life
Technologies) following the manufacturer’s instructions and kept overnight in
medium with 0.1% FBS. The next day 5 × 104 cells were seeded on human-
fibronectin-coated Biocoat Cell Culture Inserts (BD Biosciences, no. 354543) in
medium with 0.1% FBS, and the wells were loaded with complete medium. Eight
hours after the seeding, cells werewashed and fixedwith 4%paraformaldehyde. Cells
on the apical side of each insert were scraped off and themigration to the basolateral
side was visualized with a Nikon Eclipse TE2000-U fluorescence microscope.
Trans-endothelial migration assay. HPMEC cells (1 × 105) were seeded on
human-fibronectin-coated Biocoat Cell Culture Inserts (BD Biosciences) and
allowed to grow for four days until closing themonolayer. Tumour cells weremarked
with 5 µM CellTracker Green (Life Technologies) following the manufacturer’s
instructions and then were conditioned overnight in ECGM-MV2 (Promo Cell)
medium with 0.1% FBS and without supplements. The next day 5× 104 tumour
cells were seeded into Trans-well inserts with an endothelial monolayer in
ECGM-MV2 medium with 0.1% FBS and the wells were loaded with complete
medium. Eight hours after the seeding, cells were washed and fixed with 4%
paraformaldehyde. Cells on the apical side of each insert were scraped off and the
migration to the basolateral side was visualized with a Nikon Eclipse TE2000-U
fluorescence microscope.
Invasion assay.Cells weremarkedwith 5 µMCellTrackerGreen (Life Technologies)
following the manufacturer’s instructions and were kept overnight in medium
with 0.1% FBS. The next day, 5× 104 cells were seeded on BD BioCoat Matrigel
Invasion Chambers in medium with 0.1% FBS, and the wells were loaded with
complete medium. Eight hours after the seeding, cells were washed and fixed with
4% paraformaldehyde. Cells on the apical side of each insert were scraped off and
the migration to the basolateral side was visualized with a Nikon Eclipse TE2000-U
fluorescence microscope.
Flow cytometry analysis. 2× 105 HPMEC cells were seeded in ECGM-MV2
(Promo Cell) complete medium. The following day cells were washed with PBS and
treated for 4 h with PTHLH in ECGM-MV2 medium with 0.1%FBS and without
supplements. In experiments where Z-VAD-fmk (Bachem) inhibitor was used cells
were pretreated for 2 h with this pan-caspase inhibitor before PTHLH was added.
Cells were stainedwithAnnexinVApoptosisDetectionKit (SantaCruz, sc-4252AK)
following the manufacturer’s instruction. Data were obtained using a BD FACSAria
cell sorter and analysed using FlowJo software.
Western blot analysis. Protein extracts obtained from whole-cell lysates (35 µg)
were fractionated in SDS–PAGE gels, transferred onto Immobilion-P (Millipore)
membranes, and subjected to immunoblot analysis according to standard
procedures. The following antibodies were used: rabbit polyclonal antibodies to
phospho-p38 (Cell Signaling, no. 9211; dilution 1:500), goat polyclonal antibodies
against p38α (Santa Cruz, no. sc-525-G; dilution 1:500), a home-made rabbit
antiserum against MKK6 (ref. 38), rabbit monoclonal against phospho-ERK1/2
(Cell Signaling, no. 4377S; dilution 1:500), rabbit polyclonal against ERK1/2 (Cell
Signaling no. 9102; dilution 1:500), mouse monoclonal against anti-phospho JNK
(BD Transduction Laboratories, no. 612541; dilution 1:500), rabbit polyclonal
against JNK (Santa Cruz, no. sc-571; dilution 1:500), rabbit polyclonal against
PARP (Cell Signaling no. 9542; dilution 1:500), rabbit polyclonal against caspase-3
(Cell Signaling no. 9662; dilution 1:500), rabbit polyclonal against caspase-7 (Cell
Signaling no. 9492; dilution 1:500), rabbit polyclonal against AIF (AIFM1; Cell
Signaling no. 4642; dilution 1:500), rabbit polyclonal against Bid (Cell Signaling
no. 2002; dilution 1:1,000), rabbit polyclonal against Bak (Cell Signaling no. 3814;
dilution 1:1,000), rabbit monoclonal against Bcl-xl (Cell Signaling no. 2764, clone
54H6; dilution 1:500), rabbit monoclonal against Mcl-1 (Cell Signaling no. 5453,
clone D35A5; dilution 1:500) and mouse monoclonal antibody against Tom20
(Santa Cruz, sc-17764, clone F-10; dilution 1:500) and against tubulin (Sigma no.
T5168, clone B-5-1-2; dilution 1:5,000).
Primary antibodies were detected with appropriate HRP-conjugated secondary
antibodies against mouse (Cell Signaling no. 7076, dilution 1:5,000), rabbit (GE
Healthcare UK Limited, no. LNA934V dilution 1:5,000) or goat IgGs (Santa Cruz no.
sc-2020, dilution 1:5,000). Separation of cytoplasmic and mitochondrial fractions
was done using Mito Isolation Kit for Mammalian Cells (Thermo Scientific)
following the manufacturer’s instructions.
Quantitative RT–PCR analysis. Real-time qPCR was performed using TaqMan
Gene Expression Assay PTHLH probe Hs 00174969_m1; MKK6/MAP2K6 probe
Hs00992389_m1 and ABI Prism Fast 7900HT Instrument. The levels of expression
were normalized to human B2M (Applied Biosystems) and data were analysed using
the comparative1CT method.
Histopathology and immunohistochemistry. Tissues were dissected, fixed in
10%-buffered formalin (Sigma) and embedded in paraffin. Sections (2–3 µm thick)
were stained with haematoxylin and eosin (H&E). For immunohistochemistry rat
polyclonal rabbit polyclonal antibodies against GFP (Abcam, ab13970; dilution
1:2,000) and P-p38 (Cell Signaling, no. 9211; dilution 1:1,000) were used.
Immunofluorescence.HPMEC cells were grown to confluence on glass coverslips.
The cells were fixed for 10min in 10% neutral buffered formalin solution (Sigma)
at room temperature and incubated for 5 min in 0.1% Triton X-100 in PBS. Next,
the samples were blocked with 1% BSA for 30min and then stained for 20min with
rhodamine phalloidin (Life Technologies, no. R415) and DAPI (Sigma).
For AIF staining 5× 104 of HPMEC cells were seeded on glass coverslips.
The next day, cells were treated for 4 h with 1.25mM PTHLH in 0.1%FBS
ECGM-MV2 (Promo Cell) medium without supplements and stained with 80 nM
MitoTracker Red CMXRos (Lonza no. PA3017) for 15min. Next, cells were fixed
in complete growth medium containing 3.7% formaldehyde for 15min at 37 ◦C and
permeabilized for 10min in PBS containing 0.2% Triton X-100. Blocking was done
in PBS containing 3%BSA for 1 h at room temperature. Samples were incubatedwith
AIF (AIFM1) antibody (Cell Signaling no. 4642; dilution 1:100) overnight at 4 ◦Cand
1 h at room temperature with secondary antibody that recognizes rabbit IgGs (Alexa
Fluor 488, Molecular Probes Invitrogen) and mounted with ProLong Gold antifade
reagent with DAPI.
For PTHLH immunofluorescence LiM2 and PTHLH-overexpressing LiM2 cells
were seeded on glass coverslips. Next, cells were fixed with 4% PFA for 15min at
room temperature and permeabilized for 10min in PBS containing 0.2% Triton
X-100. Blocking was performed in PBS containing 3% BSA for 1 h at room
temperature. Samples were incubated with PTHLH antibody (Abcam Ab115488;
dilution 1:100) overnight at 4 ◦C and 1 h at room temperature with secondary
antibody that recognizes mouse IgGs and mounted with ProLong Gold antifade
reagent with DAPI.
PTHLH ELISA assay. For the ELISA assay, 36.4 µg of total protein lysate was used.
ELISA was purchased from Uscn Life Science (USA) and performed following the
manufacturer’s instructions.
TUNEL assay. For the TUNEL assay formalin-fixed paraffin-embedded sections
were used. In Situ Cell Death Detection Kit was purchased from Roche and assay
was used following the manufacturer’s instructions.
Live-cell imaging for intracellular Ca2+ level detection.HPMEC cells (3×105)
were seeded on 14mm glass coverslips. The next day, cells were washed and treated
for 15min with 1 µM Fluo-4 AM (Life Technologies, no. F14201) in ECGM-MV2
mediumwithout supplements. Next, the cells weremounted in a special chamber for
live-cell imaging using a Scan∧ROlympus microscope and images were taken every
second. Obtained videos were analysed using Fiji software.
Human samples. Informed consentwas obtained prospectively before surgery from
each patient and a total of 23 primary tumours and healthy mucosa were obtained.
Patient identifiers were removed from the samples to protect patient confidentiality
as per institutional guidelines. All human samples were manipulated with the
approval and following the guidelines of the Ethic Committee of Hospital Clinic de
Barcelona and IRB-Barcelona. Information on tumour relapse and follow-up was
extracted from the medical records; patients were followed with CT scan every three
months. Owing to the lack of material 3 samples could be subjected only to mRNA
isolation whereas the rest were subjected to both mRNA and protein isolation.
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Clinical sample analysis. Authorization was obtained to analyse a database of 100
metastatic colorectal cancer (CRC) patients treated with irinotecan and cetuximab
inside a phase II translational trial39 and 40 localized patients from a single cohort
prospective study40 that relapsed during the study follow-up. Site of metastasis
was extracted and tabulated by primary site (colon versus rectum) with basic
descriptive statistics.
Mass spectrometry analysis. Proteins were digested with trypsin following
standard protocols. Briefly, 50 µg of sample was reduced with 2mM dithiothreitol.
After 1 h at 25 ◦C, iodoacetamide was added to a final concentration of 7mM
and the samples were incubated for 30min in the darkness. The reaction was
stopped by adding 2mM dithiothreitol. Then, proteins were digested with trypsin
and incubated at 37 ◦C overnight. Digestions were stopped by adding formic acid
to a final concentration of 1%. The resulting peptide mixtures were diluted in 1%
FA and loaded in a nano-LC–MS/MS system. The nano-LC–MS/MS set up was
as follows. Samples were loaded to a 180 µm ×2 cm C18 Symmetry trap column
(Waters) at a flow rate of 15 µl min−1 using a nanoAcquity Ultra Performance LCTM
chromatographic system (Waters). Peptides were separated using a C18 analytical
column (BEH130TM75 µm× 10 cm, 1.7 µm,Waters) with a 90min run, comprising
three consecutive steps with linear gradients from 1 to 35% B in 60min, from
35 to 50% B in 5min, and from 50% to 85% B in 3min, followed by isocratic
elution at 85% B in 10min and stabilization to initial conditions (A= 0.1% FA in
water, B= 0.1% FA in CH3CN). The column outlet was directly connected to an
Advion TriVersa NanoMate (Advion) fitted to an LTQ-FT Ultra mass spectrometer
(Thermo). Spray voltage in theNanoMate sourcewas set to 1.70 kV. Capillary voltage
and tube lens on the LTQ-FT were tuned to 40V and 120V. The spectrometer was
working in positive polarity mode. At least two blank runs before each analysis were
performed to ensure the absence of cross-contamination from previous samples.
To select the PTHLH-targeted ions, the mass spectrometer was operated in a data-
dependent acquisition (DDA) mode. Survey MS scans were acquired in the FT
with the resolution (defined at 400m/z) set to 100,000. Up to six of the most
intense ions per scan were fragmented and detected in the linear ion trap. The ion
count target value was 1,000,000 for the survey scan and 50,000 for the MS/MS
scan. Target ions already selected for MS/MS were dynamically excluded for 30 s. A
database search was performed with Proteome Discoverer software v1.3 (Thermo)
using the Sequest search engine and the SwissProt database (human release 12_03)
where PTHLH peptide was added. Search parameters included trypsin enzyme
specificity, allowing for two missed cleavage sites, carbamidomethyl in cysteine
as a static modification and methionine oxidation as dynamic modifications.
Peptide mass tolerance was 10 ppm and the MS/MS tolerance was 0.8 Da. Peptides
with a q value lower than 0.1 were considered as positive identifications with a
high confidence level. One peptide ion was selected for targeted MS/MS analysis:
SDQDLR (m/z 366.21). The presence of PTHLH in the samples was determined
by using the same nano-LC–MS/MS system described above. The spectrometric
analysis was performed in a targeted mode, acquiring a full MS/MS scan of
the precursor ion SDQDLR (m/z 366.21). The quantification was performed
with Xcalibur software versus 2.0SR2 (Thermo Scientific) by using extracted
ion chromatograms of the optimum MS/MS transitions in terms of sensitivity
(SDQDLR, 366.22→ 531.38).
Sample size calculation. An assessment of the number of animals required for
each procedure was performed using Statistical Power Analysis and taking into
consideration the appropriate statistical tests, significance level of 5% and statistical
power of 80%. An estimate of variance was inferred from previous experiments,
especially considering the variability of tumour xenograft growth.
Method of randomization. A method of randomization was used in the
experiment shown in Fig. 3c. Parental cells were implanted directly into the liver
in nude mice (one implant per mouse) and, when the liver tumour signal reached a
certain photon flux threshold (>1×108 photons s−1), mice were randomly allocated
to daily systemic treatment with either vehicle or PH-797804.
Group allocation. For the results obtained in Figs 5e, 6c and 7c,d and
Supplementary Figs 1a, 3d,e, 4b,e,f and 7a,d the investigator was not aware of group
allocation when assessing the outcome.
Data sets analysed. GSE17538 is a metacohort composed of 177 colon cancer
patients treated at H. Lee Moffitt Cancer Center (Tampa, USA) plus 55 colon cancer
patients treated at Vanderbilt University Medical Center (Vanderbilt, USA; ref. 41).
Note that this cohort did not include rectal cancers. GSE14333 contains a pool of
290 CRC patients treated at two different hospitals: PeterMacCallumCancer Center
(Australia) and H. Lee Moffitt Cancer Center (USA; ref. 42). We combined both
cohorts for a total of 340 CRC expression data sets fromwhich we used 267 (stages I,
II and III).Note that theGSE17538 andGSE14333 cohortswere partially overlapping
owing to patients treated at H. Lee Moffitt Cancer Center being duplicated in both
data sets. Duplicated cases were included only once in the final selection. To remove
biases due to the data having been collected in different hospitals, we computed
z-scores (that is, subtracted the mean and divided by the standard deviation) for
each gene and hospital separately before merging them into a meta-cohort.
Accession number of data set generated for this study (Fig. 2a): GSE33350.
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Supplementary Figure 1 Characterization of liver and lung metastatic potential 
of SW620 parental and LiM2 cells. (a) Invasion capacity of SW620 parental 
and LiM2 cells was measured using matrigel-coated Boyden chambers. 
Results represent values of three independent experiments where each cell 
line was seeded in six Boyden chambers and five fields per chamber were 
analyzed and average for each chamber obtained (n=18 chambers per group). 
Statistical significance was calculated using two-tailed Mann Whitney test; 
the box extends from 25 to 75 percentile where black line within the box 
represents median, whiskers extend from 10 to 90 percentile. (b) In vivo 
proliferation of parental and LiM2 cells (0.5x105) injected into cecum of nude 
mice. Bioluminescent images were taken at day 54. n =8 (Parental) and n=9 
(LiM2) number of mice used for each cell line. Statistical analysis was done 
using two-tailed Mann Whitney test and no statistically significant differences 
were found. (c) Percentage of lymph node and liver metastasis as well as lung 
metastasis in mice that developed liver metastasis upon intracecum injections 
of parental and LiM2 cells determined post-mortem. Number of mice (n) 
used is defined in (b). Statistical significance was calculated using one-sided 
Fisher’s exact test. (d) Representative bioluminescent images of intestine, liver 
and lung from mice injected intracecum with SW620 parental and LiM2 cells. 
Data is presented as average plus s.d.
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Supplementary Figure 2
CRC human tumor samples. Stages I,II,III
             GSE17537+GSE14333
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Supplementary Figure 2 Gene set enrichment analyses (GSEA) of the CCM 
downregulated gene set and phosphorylated p38 MAPK levels in liver 
metastatic lesions formed by LiM2 cells. (a) GSEA analysis of the CCM 
downregulated gene set in human colon cancer dataset (pooled GSE17537 
and GSE14333 expression set). NES-normalized enrichment score; FDR-false 
discovery rate. (b) SW620 parental and LiM2 cells were injected intraliver and 
40 days later mice were sacrificed. Size matched liver lesions were selected for 
immunohistochemistry staining with anti- phospho-p38 (P-p38) antibodies. 
Representative IHC staining is shown where n=6 animals per group were used. 
Scale bar 500 μm; inset scale bar 50 μm; H-healthy tissue; T-tumor.
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Supplementary Figure 3
Supplementary Figure 3 ERK1 and ERK2 influence on primary tumors and 
metastasis. (a) ERK1 and ERK2 downregulation was confirmed by Western 
blotting (representative Western blots from three independent experiments 
are shown). (b) Percentage of mice intrasplenically injected with LiM2 cells 
expressing the indicated shRNAs that developed liver metastases (up) or 
lung metastasis (bottom). n= 17 (shControl), n=10 (sh1 ERK1) and n=18 
(sh2 ERK1) number of mice used per group pooled from two independent 
experiments. Statistical analysis was done using two-sided Fisher’s exact 
test. n.s.- not significant. (c) LiM2 cells expressing the indicated shRNAs 
were injected orthotopically into mice cecum and growth rates by photon flux 
quantification were determined. n=9 (shControl), n=9 (sh1 ERK1), n=8 (sh2 
ERK1), n=10 (sh1 ERK2), n=8 (sh2 ERK2) number of mice used per group. 
Data is presented as average plus s.d. Statistical analysis was done using 
one-way ANOVA and no statistical differences were found. (d and e) Size 
matched lesions from (c) were selected for immunohistochemistry Ki-67 
(d) and cleaved caspase-3 staining (e). n=20 total fields per group analyzed 
where five different fields from size matched lesions per mouse were 
quantified. Number of mice used in each group was 4. Statistical analysis 
was done using two-tailed Mann Whitney test. All values are presented in 
the graphs together with average ±s.d. (f) Kaplan-Meier curves representing 
association of proportion of recurrence-free patients with relative FRA1 gene 
expression levels in human primary colon cancer dataset (pooled GSE17537 
and GSE14333; n=267). HR-hazard ratio. Statistical analysis was done 
using Cox proportional hazard’s model.
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Supplementary Figure 4 Lung metastasis in colon cancer associates with 
low levels of phopsho-p38 MAPK in primary tumors. (a) Association of lung 
metastasis with levels of phosphorylated p38 (P-p38) protein in samples 
of 7 primary CRC tumor samples that developed metastasis. P-p38 levels 
were normalized to p38 total amount of protein and P-p38 expressed in the 
respective healthy mucosa samples. n=3 tumors with lung mets and n=4 
tumors with other mets. Statistical analysis was done using one-tailed Mann 
Whitney test. (b) HCT116 cells expressing p38α shRNAs or constitutively 
active MKK6EE were injected orthotopically into mice cecum and size 
matched lesions were selected for Ki-67 and cleaved caspase-3 staining. 
Five different fields per lesion and mouse for Ki67 staining and ten different 
fields /lesion/mouse for cleaved caspase-3 staining were scored. n=40 
(Mock), n=30 (sh p38 α) and n=40 (MKK6EE) total number of fields per 
group analyzed for Ki67 staining. n=80 (Mock), n=60 (sh p38 α) and n=80 
(MKK6EE) total number of fields per group analyzed for cleaved caspase-3 
staining. (c) HCTT116 cells expressing p38α shRNAs or constitutively active 
MKK6EE were injected orthotopically into mice cecum and the percentage of 
mice that developed liver metastasis, the area of liver and lung metastasis 
were determined. #, † indicate the groups which statistically significant. # 
P=0.001; † P=0.017. Values for area represent mean ± s.e.m. n=41 (Mock), 
n=14 (sh p38 α) and n=61 (MKK6EE) number of lung lesions analyzed. (d) 
Representative H&E staining of lung and liver histological sections from 
(c). Dashed lines delineate metastasis. Scale bar 200 μm. (e) Emerging 
lung metastatic lesions from HCTT116 cells expressing p38α shRNAs or 
constitutively active MKK6EE injected orthotopically into mice cecum were 
selected for cleaved caspase-3 staining. n=9 (Mock), n=11 (sh p38 α) and 
n=5 (MKK6EE) total number of lesions analyzed per group. (f) Emerging lung 
metastatic lesions from SW620 parental and LiM2 cells were selected for 
cleaved caspase-3 staining. n=6 (Parental) and n=9 (LiM2) total number 
of lesions analyzed per group. Scale bar 50 μm. For (b),(c), (e) and (f) 
two-tailed Mann Whitney test was used for statistical analysis; n.s.- not 
significant. In panels (a), (b), and (f) all values are presented in the graphs 
together with average ±s.d. In panel (e) all values are presented in the graph 
together with average plus s.d.
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Supplementary Figure 5
P=0.038
Supplementary Figure 5 PTHLH gene expression is associated with poor 
clinical outcome in patients with colon cancer. (a) Kaplan-Meier curves 
representing association of proportion of recurrence-free patients with 
relative PTHLH gene expression levels in human primary colon cancer 
dataset (pooled GSE17537 and GSE14333; n=267). HR-hazard ratio. 
Statistical analysis was done using Cox proportional hazard’s model. (b 
and c) ELISA analysis of PTHLH levels in HCTT116 cells (n=3 values from 
independent experiments) expressing constitutively active MKK6EE (b) 
or immunofluorescence analysis of PTHLH levels (representative images 
from two independent experiments) in SW620 cells expressing PTHLH (c). 
Statistical analysis was done using one-tailed Student’s t test in (b) and 
graphs represent average plus s.d. Scale bar in (c) 50μM. (d) Detection of 
PTHLH by mass-spec analysis in conditioned medium from SW620 parental, 
LiM2 shControl and LiM2 shPTHLH cell lines.
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Supplementary Figure 6 PTHLH does not affect the growth of LiM2 cells 
in the lung. (a) Photon flux of dorsal upper back area of mice injected 
intrapulmonary with LiM2 cells expressing two different shRNA against 
PTHLH. Normalization was done to values of day 0. n=9 (sh Control), n=9 
(sh1 PTHLH) and n=9 (sh2 PTHLH) number of mice used per group. Inset 
represents qRT-PCR analysis of PTHLH expression levels in LiM2 cells 
infected with lentivirus expressing shRNA against PTHLH or the control 
shRNA in three independent experiments (n=3). Statistical analysis for 
main graph was done using two-tailed Mann Whitney test and no statistically 
significant differences were found. Statistics for the graph presented 
in inset was done using two-tailed Student’s t test. ** P<0.001. Values 
represented in the main graph as well as in inset represent average plus s.d. 
(b) Representative bioluminescent images of mice injected intrapulmonary 
with LiM2 cells expressing two different shRNAs against PTHLH. (c) Lung 
metastasis-free survival of mice (n = 14) upon tail vein injection of LiM2 
cells. Representative bioluminescent images are shown.
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Supplementary Figure 7 Effect of PTHLH on endothelial cells of the lung. 
(a) Migration of LiM2 cells mock infected or infected with a retrovirus that 
expresses PTHLH was scored in Boyden chambers covered with fibronectin 
or with fibronectin and HPMEC monolayer. Each cell line was seeded 
in triplicate and 5 fields per chamber were counted. Results represent 
three independent experiments for migration through fibronectin and four 
independent experiments for migration through fibronectin and HPMEC 
monolayer. n=45 total number of fields analyzed per group for migration 
through fibronectin  and n=60 total number of fields analyzed per group for 
migration through fibronectin and HPMEC monolayer. Statistical analysis 
was done using two-tailed Mann Whitney test (b) Western blot analysis of 
PTH1R expression levels in HPMEC cells (representative images from two 
independent experiments). Tubulin was used as a loading control. (c) HPMEC 
cells were grown until reaching tight confluence and then were treated for 24 
h with conditioned medium from SW620 parental, LiM2, LiM2 shPTHLH and 
LiM2 treated cells with PTHLH-Antagonist Peptide (AP). Phalloidin staining 
was performed and total gap area per field was determined. Results represent 
values of three independent experiments where each sample was seeded in 
duplicate and for each coverslip at least 5 fields were analyzed. n=40,40,40 
and 30 total number of fields analyzed per group respectively. Statistical 
analysis was done using two-tailed Student’s t test; scale bar 100 μm. (d) 
Average number of TUNEL-positive cells in ovary or liver 4 h post tail vein 
injection of recombinant PTHLH (1-34). Three 30 μm distant sections per 
animal were counted. PBS, 1 nM, 10 nM, and 100 nM rPTHLH (5 mice per 
group). n=15 total number of sections analyzed per group. Statistical analysis 
was done using two-tailed Mann Whitney test; n.s.-not significant. All values 
are presented in the graphs together with average ±s.d. (e) Western blot 
analysis of total and cleaved PARP, Caspases-3 and Caspases-7 in HPMEC 
cells treated for 20 h with PTHLH or Staurosporine. Tubulin was used as a 
loading control.  (f) Western blot analysis of pro-apoptotic and anti-apoptotic 
protein levels in HPMEC cells upon 4 h treatment with the indicated doses of 
recombinant PTHLH. Tubulin was used as a loading control. (g) HPMEC cells 
were treated for 4 h with the indicated doses of recombinant PTHLH and the 
cytosolic and mitochondrial fractions were isolated and subjected to western 
blot analysis for AIFM1 protein expression levels. Tom 20 was used as a 
loading control of mitochondria and tubulin as a loading control of cytosol. 
In panels (a) and (c) the box extends from 25 to 75 percentile where black 
line within the box represents median, the whiskers extend from 10 to 90 
percentile. Western blot images in (e), (f) and (g) are representative from at 
least two independent experiments.
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Supplementary Video Legend
Supplementary Video 1 PTHLH treatment increases intracellular Ca2+ levels. Cells were treated for 15 min with Fluo4-AM calcium indicator and then 
imaged for 9 min. First two minutes of imaging were used for determining the basal Ca2+ levels. At min 2, control media was added to cells and at min 5 
media with 1.25μM recombinant PTHLH.
Supplementary Table Legends
Supplementary Table 1 Genes differentially expressed between Parental and LiM2 cells. Comparative genome-wide expression analysis of genes that were 
overexpressed or underexpressed at least 2.5-fold in the highly liver metastatic derivative LiM2 compared to parental cells
Supplementary Table 2 BGSEA for KEGG gene sets (Parental vs. LiM2). By using BGSEA we identified pathway-specific gene expression signatures (KEGG 
gene sets) that were differentially represented in the gene expression profiles of parental and LiM2 cells.
Supplementary Table 3 Frequency of liver and lung metastasis in a pooled analysis of patients with metastatic colon and rectal cancers. Frequency of liver 
and lung metastasis in a pooled analysis of patients with metastatic colon and rectal cancers with clinical annotation for the site of metastasis.
Supplementary Table 4 Genes differentially expressed in LiM2 cells compared to Parental that correlated significantly with MKK6 expression in CRC primary 
tumors. Genes differentially expressed in LiM2 cells compared to Parental (fc>1.7) that correlated significantly (p<0.05) with MKK6 expression in Stage II 
and III CRC primary tumors.
© 2014 Macmillan Publishers Limited. All rights reserved. 
 
Accession Entrezid Symbol Fold change ProbDE LiM2 upregulated (1) LiM2 downregulated (-1)
7968678 341640 FREM2 24.08653858 0.999999949 1
8044225 27233 SULT1C4 26.52948714 0.999999928 1
7971150 10186 LHFP 10.82175184 0.999999913 1
8150529 27121 DKK4 9.067136049 0.999999864 1
7996819 1001 CDH3 8.893116512 0.999999697 1
8120654 56479 KCNQ5 6.617315074 0.999999694 1
8151369 157869 C8orf84 8.235975632 0.999999669 1
8123246 6581 SLC22A3 -13.20478963 0.999999575 -1
8149142 1670 DEFA5 21.4552802 0.999999502 1
7955963 118430 MUCL1 17.42689016 0.999999479 1
7943892 4684 NCAM1 -6.896299997 0.999999179 -1
8018652 114804 RNF157 -5.115656414 0.999999012 -1
7985159 1381 CRABP1 -10.74399738 0.99999859 -1
8054451 10913 EDAR 9.789151555 0.999998519 1
8149465 26281 FGF20 17.05711611 0.999998482 1
8149927 1191 CLU 5.789090398 0.999998422 1
8162502 2203 FBP1 5.443603034 0.999998393 1
7989199 8854 ALDH1A2 4.239215443 0.999998251 1
7962455 4753 NELL2 8.873481898 0.999998119 1
7932243 221061 FAM171A1 3.696377047 0.999998079 1
8044154 926 CD8B 5.892235369 0.999997984 1
7940409 921 CD5 5.735089339 0.999997852 1
7963427 3852 KRT5 10.01237522 0.999997749 1
8121850 23493 HEY2 8.748918888 0.999997527 1
8138381 10551 AGR2 8.528661076 0.999997501 1
7990714 1136 CHRNA3 5.375162024 0.99999743 1
8040365 28951 TRIB2 3.575833149 0.999997282 1
8068651 5121 PCP4 -5.787313903 0.999997275 -1
8107823 171019 ADAMTS19 6.278995307 0.999997225 1
8169145 139221 MUM1L1 6.060861226 0.999996884 1
8102232 51176 LEF1 7.6912546 0.999996553 1
8081590 90102 PHLDB2 8.145721728 0.999996409 1
7944769 57476 GRAMD1B -5.451589415 0.99999604 -1
8073088 60489 APOBEC3G 5.317387373 0.99999597 1
8113130 79772 MCTP1 6.63524134 0.999995795 1
8117054 10486 CAP2 -4.231752363 0.999995599 -1
7953200 894 CCND2 5.053642341 0.99999558 1
8078066 152273 FGD5 -5.030668514 0.999995406 -1
8020455 2627 GATA6 -3.908156132 0.99999537 -1
8115147 972 CD74 3.183285686 0.999995365 1
7913237 55450 CAMK2N1 -5.705441 0.999995365 -1
8148040 114569 MAL2 10.90406283 0.999995127 1
8020141 147495 APCDD1 3.628691314 0.999994847 1
7925929 8644 AKR1C3 -4.030067133 0.999994826 -1
7948332 9404 LPXN 3.336534706 0.999994727 1
7977046 7127 TNFAIP2 4.242035576 0.999993157 1
7965403 4060 LUM -6.128287931 0.999993055 -1
Supplementary Table 1. Genes differentially expressed between Parental and LiM2 cells 
(cut off 2.5)
set KEGGterm probEnriched
4010 MAPK signaling pathway 1
4514 Cell adhesion molecules (CAMs) 1
910 Nitrogen metabolism 1
120 Primary bile acid biosynthesis 1
532 Chondroitin sulfate biosynthesis 1
561 Glycerolipid metabolism 1
4360 Axon guidance 1
4512 ECM-receptor interaction 1
4950 Maturity onset diabetes of the young 1
5200 Pathways in cancer 1
534 Heparan sulfate biosynthesis 1
4510 Focal adhesion 1
600 Sphingolipid metabolism 1
3320 PPAR signaling pathway 1
4520 Adherens junction 1
4660 T cell receptor signaling pathway 1
4670 Leukocyte transendothelial migration 1
5218 Melanoma 1
5410 Hypertrophic cardiomyopathy (HCM) 0.99
51 Fructose and mannose metabolism 0.99
4810 Regulation of actin cytoskeleton 0.99
5412 Arrhythmogenic right ventricular cardiomyopathy (ARVC) 0.99
4310 Wnt signaling pathway 0.99
4920 Adipocytokine signaling pathway 0.98
4350 TGF-beta signaling pathway 0.98
5222 Small cell lung cancer 0.98
4020 Calcium signaling pathway 0.98
510 N-Glycan biosynthesis 0.98
2010 ABC transporters 0.97
4666 Fc gamma R-mediated phagocytosis 0.97
564 Glycerophospholipid metabolism 0.97
4060 Cytokine-cytokine receptor interaction 0.97
4070 Phosphatidylinositol signaling system 0.97
790 Folate biosynthesis 0.96
512 O-Glycan biosynthesis 0.96
5212 Pancreatic cancer 0.95
361 gamma-Hexachlorocyclohexane degradation 0.95
360 Phenylalanine metabolism 0.95
Supplementary Table 2. BGSEA for KEGG gene sets (Parental vs. LiM2)
Patients with only liver 
metastasis (%)
Patients with only lung 
metastasis (%)
Patients with liver and 
lung metastasis (%)
Total number of 
patients*
Colon cancer 40 (42.6) 3 (3.2) 23 (24.5) 94
Rectal cancer 11 (23.9) 12 (26) 13 (28.3) 46
* Some of the patients developed metastasis is sites other than liver and lung.
Pooled analysis of patients from references 1 and 2 of supplementary information.
Supplementary Table 3. Frequency of liver and lung metastasis in a pooled analysis of patients with metastatic colon and rectal cancers
Entrezid Symbol Probeid
29974 A1CF 220951_s_at
257629 ANKS4B 239087_at
10123 ARL4C 202207_at
81563 C1orf21 223127_s_at
814 CAMK4 210349_at
50515 CHST11 226372_at
119467 CLRN3 229777_at
1644 DDC 214347_s_at
2918 GRM8 216255_s_at
3174 HNF4G 207456_at
5654 HTRA1 201185_at
10186 LHFP 218656_s_at
5744 PTHLH 211756_at
54502 RBM47 229439_s_at
6038 RNASE4 205158_at
6515 SLC2A3 202499_s_at
54843 SYTL2 220613_s_at
7113 TMPRSS2 1570433_at
28951 TRIB2 202478_at
128553 TSHZ2 244521_at
7103 TSPAN8 203824_at
Supplementary Table 4. Genes differentially 
expressed in LiM2 cells compared to Parental 
(fc>1.7) that correlated significantly (p<0.05) 
with MKK6 expression in Stage II and III CRC 
primary tumors
In Bold, highlighted genes whose change of 
expression in SW620 cells liver metastatic 
derivatives compared to parental is concordant to 
that found in patients CRC primary tumors that 
correlate with MKK6 expression.
5Discussion
We used two diverse and complementary approaches to shed light on the biology that
drives the clinical behavior of CRC.
In the first place, we have used a modern epidemiology approach combining a
prospective cohort of healthy individuals where we identified incident cases of CRC
with genotyping techniques and histological characterization of the tumors. The use
of a prospectively collected detailed data on CRC risk factors over a long-term follow-
up allowed us to account for the main potential confounders of our association. We
found that in this study, involving 1509 cases of CRC and 2307 controls nested in the
two prospective cohorts, the CRC-susceptibility locus SMAD7 intronic rs4939827 was
associated with a lower risk of CRCs with pT1 and pT2 stage but not pT3 and pT4
stage. Among patients diagnosed with CRC, those with at least one G allele had 1.5 -
fold higher odds of having a pT3 or pT4 tumor compared with a pT1 or pT2 tumor.
This finding may explain in part observed associations of the G allele of rs4939827 with
lower overall risk of incident CRC (23), but worsened survival after diagnosis (25, 112).
The seemingly contrary associations of this SNP in SMAD7 with decreased risk
of incident disease shown in GWAS studies (17, 22) but poorer outcomes in patients
with established disease may be due to SMAD7’s known involvement in modulating
the TGFβ type 1 pathway.
The SMAD7 gene codes for an intracellular protein that interacts with the TGFβ
type 1 receptor, and promotes its degradation in the proteasome therefore inhibiting
TGFβ1-induced phosphorylation of SMAD2/SMAD3 (113). SMAD7 overexpression
has been reported to be associated with the development of lung, pancreatic and skin
61
5. DISCUSSION
cancer and at the same time it can delay hepatocellular carcinoma growth and inhibit
metastasis from melanoma and breast cancer (114). SMAD7 also exerts its function via
TGFβ-independent pathways. Specifically, it downregulates CDC25A (a phosphatase
that regulates cell cycle) at a postranscriptional level (115). In normal epithelium,
TGFβ1 functions as a tumor suppressor through induction of cell arrest and inhibition
of cell proliferation. However, once cells are resistant to TGFβ1-mediated prolifera-
tive inhibition (i.e. in established tumors), TGFβ1 appears to promote metastasis by
enhancing angiogenesis and extracellular matrix disruption and inhibiting infiltrating
tumor immune cells.
We also found an association of rs4939827 with RUNX3 methylation status in the
tumors, which supports a role of rs4939827 in the TGFβ1 pathway. RUNX3 is a Runt
domain transcription factor 3 involved in TGFβ1 signaling by interaction with SMAD
transcription factors and it is considered a suppressor of solid tumors. The RUNX3
promoter is commonly aberrantly methylated in a CpG island in CRC (116, 117, 118),
leading to gene inactivation. RUNX3 is a downstream target of the TGFβ pathway.
Specifically, RUNX3 is involved in mediating TGFβ-induced apoptosis. RUNX3 an-
tagonizes the oncogenic Wnt pathway in CRC carcinogenesis by binding directly to the
T-cell factor 4 (TCF4) and forming a ternary complex with β-catenin that negatively
regulates the transcriptional activity of Wnt target genes (119). RUNX3 also acts as
a downstream target of the bone morphogenetic proteins (proteins that belong to the
TGFβ superfamily with a wide range of functions, including proliferation and apopto-
sis) and exerts its tumor suppressor effect by inhibiting c-Myc (120). RUNX3 SNPs
are associated with survival after a diagnosis of CRC (121). Differential methylation
of RUNX3 according to rs4939827 could help explain the worsened survival among
individuals with CRC who have a variant G allele (121). TGFβ and Wnt signaling are
involved in the induction of epithelial-mesenchymal transition, a process that mediates
invasion and metastasis in CRC. However, our mediation analysis does not suggest that
the association between rs4939827 on risk of CRC according to pT stage is primarily
related to RUNX3. Nonetheless, the mediation analysis should be interpreted in the
context of some limitations (111), including the assumption of a lack of other, strong
unmeasured confounders.
We also examined several other molecular markers besides RUNX3 and did not
observe relevant differences in the association with rs4939827. BRAF status did appear
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to be differentially associated with rs4939827 (uncorrected p value=0.02), despite the
lack of a significant p value for heterogeneity after correction for multiple comparisons.
Given that an interplay between TGFβ and BRAF mutations is biologically plausible
(122) and that BRAF mutations are relative rare and strongly associated with CRC
prognosis (123, 124), we cannot rule out that in a larger sample size such heterogeneity
might have been more evident. A previous study that also studied the heterogeneity
in associations of rs4939827 with CIMP status, MSI, KRAS or p53 mutational status
did not find any relevant association (121).
In the second place, we used a bench approach based on cell lines and animal models
merged with publically available clinical data to investigate mechanisms of metastasis
in CRC, taking advantadge of high-throughput gene expression technology. Research
on biology of metastasis has progressed in the last decade, throwing light on many of
the processes involved: angiogenesis, the role of the stroma, EMT and mesenchimal-to-
epithelial transition, intravasation, circulation, extravasation, survival upon arrival to
the distant organ, stemness, the role of metastatic niches and celullar latency (71, 81).
Here we describe a novel “metastasis from metastasis” mechanism of CRC spread.
Liver is the predominant site of CRC; nevertheless, a small set of patients with KRAS
mutant tumors can also present lung metastasis with an enrichment of KRAS mutations
(125). We provide evidence for a distinct mechanism that relies on different signalling
pathways whose hierarchical modulation enhances the ability of departing tumour cells
to consecutively seed the liver and the lungs.
After enriching the liver metastatic capacity of a mutant KRAS cell line, colaterally
the lung metastatic capacity was also enhanced. Through mRNA expression and path-
way analysis we identified a high activity of ERK1/2 and low levels of p38 as plausible
mediators. Reinforcing these findings, a low ERK/p38 signal ratio was found in fresh
tumor biopsies from CRC patients with liver metastasis as compared with patients
without metastasis after two years of follow-up from primary tumor surgery. This is
in line with previous studies that have shown that ERK signaling favors circulating
tumor cells colonization and growth (126). Notably, we propose that p38 inhibition
is required for lung colonization exclusively and that this is mediated by the cytokine
PTHLH. Loss of p38 induces PHTLH which in turn induces caspase-independent en-
dothelial cell death allowing extravasation of circulating tumor cells into the lung.
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Our study confronts previous evidence claiming “distant metastasis do not metas-
tasize” (127). The study of Holzel et.al. argues, using breast cancer data from a
national tumor registry and analyzing the relationship of metastasis-free survival or
overall survival with primary tumor size and lymph node involvement, that all the
metastasis happen before primary tumor retrieval (127). They do not provide any
experimental evidence to support their claim. Metastatic cancer cells need to gain a
number of functions in order to be able to generate overt metastases (i.e. angiogenesis,
stroma activation, invasion, EMT, intravasation, circulation, extravasation, survival
on the distant organ, stemness, immune evasion, cellular latency, reactivation, special-
ized cooption, recirculation (81)). It seems unlikely that cells that have gained these
functions and have been able to colonize a distant organ cannot repeat the process to
colonize a second one. Experimental evidence shows that metastatic cells can seed the
primary tumor with more efficiency than their corresponding parental lines (49).
Our results indicate that genetic changes that allow cancer cells to efficiently metas-
tatize to the liver must be followed by additional genetic alterations that allow sec-
ondary metastases from the liver to the lung, emphasizing the concept of “metastases
from metastases”. We illustrate the systemic contribution of PTHLH released from
tumor cells in supporting distant metastatic processes by triggering vascular perme-
ability. The expression of PTHLH is higher in CRC tissue than in normal colorectal
mucosa or polyps (128), and our findings emphasize the ability of PTHLH to trigger
caspase-independent cell death at the lung vasculature as a novel contributor to the
hierarchical process of metastasis in CRC. Previous studies have implicated PTHLH
in breast and squamous cell carcinoma tumour progression to bone metastasis through
its activity in the bone remodelling process (129, 130, 131).
The observation that liver and lung colonization are linked to tumour-specific or
circulating cell-specific factors may help create new therapeutic opportunities and also
opens new questions that can help understand the biology of the evolution of CRC.
Based on our results, Bragado et al. hypothesized that, given that TGFβ2 and BMPs
can induce dormancy post extravasation by establishing a low ERK/p38 signaling ratio
(126, 132), our cell line with higher metastatic capacity might have regained sensitivity
to dormancy signals via p38 activation. This opens new research opportunities and
enrich the research field on metastasis of CRC.
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6Conclusions
• Patients with the rs4939827 CRC-susceptibility locus diagnosed with CRC tend
to develop tumors with greater invasiveness (as measured by the pT stage).
• The variant rs4939827 is differentially associated with RUNX3 methylation sta-
tus, supporting an effect of rs4939827 or causal variants tagged by this SNP on
carcinogenesis mediated through the TGFβ pathway. Taken together, these re-
sults could explain, at least in part, the lower risk of CRC associated with the G
allele of rs4939827 yet poorer survival.
• ERK2 activation provides colon cancer cells with the ability to seed and colonize
the liver.
• Reduced p38 MAPK signalling endows cancer cells with the ability to form
lung metastasis from previously established liver lesions. Downregulation of p38
MAPK signalling results in increased expression of the cytokine PTHLH, which
contributes to colon cancer cell extravasation to the lung by inducing caspase-
independent death in endothelial cells of the lung microvasculature.
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